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Male breast cancer is a rare disease, accounting for about 0.5% of the total number of
breast cancer cases in Scotland. Less is therefore known about the potential genetic
influences in its development than for female breast cancer. A number of previous
studies have found mutations of the androgen receptor gene and the BRCA2 gene in
male breast cancer cases. Polymorphisms in the CYP17, CYP19 and estrogen
receptor genes have been associated with an increased risk of female breast cancer.
METHODS
DNA was obtained from 64 male breast cancer cases treated in the Department of
Clinical Oncology, Western General Hospital, Edinburgh between 1974 and 1998.
The DNA was screened for mutations in the entire BRCA2 gene. Frequencies of
polymorphisms in the androgen receptor gene, CYP17, CYP19 and estrogen receptor
genes were studied in the 64 cases and in a control population. Family pedigrees for
the 64 cases were constructed where possible. Clinical data were retrieved from
hospital casenotes.
RESULTS / CONCLUSIONS
Germline BRCA2 mutations were identified in 12 of the 64 (19%) male breast cancer
cases. This is an appreciably higher proportion than previously recorded for U.K.
populations. A polymorphism in exon 2 of BRCA2 was found significantly more
frequently in male breast cancer patients than in controls. The effects of this
polymorphism, particularly upon gene expression, require further evaluation.
BRCA2 mutations in male breast cancer are not necessarily associated with a
positive family history of breast cancer, although half of our series did have affected
relatives. In four additional cases, a positive family history was found despite
absence of a demonstrable BRCA2 mutation. From the family pedigrees, breast
cancer penetrance for the BRCA2 mutations detected as a whole in females by age
73, is estimated at about 62%.
There were no significant differences between the male breast cancer patients found
to carry germline BRCA2 mutations compared to those without mutations, in terms
ofmean age at diagnosis, histological classification of tumours, disease stage at
presentation, or survival.
Polymorphic alleles of the CYP17 gene and exon 2 of the estrogen receptor gene are
found significantly more frequently in male breast cancer patients than in controls.
There were no significant differences in the distribution of alleles of the androgen
receptor gene or CYP19 gene between male breast cancer patients and controls.
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1.1 The First Recorded Case Of Male Breast Cancer
The first description of an apparent case of male breast cancer was recorded in the
Edwin Smith Papyrus. This ancient Egyptian document was written in the
seventeenth century B.C. However, it is believed to be a copy of a manuscript written
sometime between 2500 and 3000 B.C. It is speculated that Imhotep, chief physician
to the pharaoh in the thirtieth century B.C., may have written the original document
(Encyclopaedia Britannica Online). The papyrus was acquired in 1862 by an
American named Edwin Smith. After Edwin Smith's death in 1906, the papyrus was
given to the New York Historical Society by his daughter. In 1930, an American
Egyptologist, James Breasted, published a translation. The Edwin Smith Papyrus is
organized in a series of 48 surgical cases. A direct copy of the translation of Case 45
is given below (Breasted, 1930). A photograph of the relevant section of the original
papyrus is shown in Figure IT.
TITLE : Instructions Concerning Bulging Tumors On His Breast
EXAMINATION : If thou examinest a man having tumors on his breast, (and) thou
findest that [swellings] have spread over his breast; if thou puttest thy hand upon his
breast upon these tumors, (and) thou findest them very cool, there being no fever at
all therein when thy hand touches him; they have no granulation, they form no fluid,
they do not generate secretions of fluid, and they are bulging to thy hand.
DIAGNOSIS : Thou shouldst say concerning him : "One having tumors. An ailment
with which I will contend."
TREATMENT
There is no treatment. If thou findest tumors in any member of a man, thou shalt treat
him according to these directions.
As for "Bulging tumors on his breast," it means the existence of swellings on his
breast, large, spreading and hard; touching them is like touching a ball of wrappings;
the comparison is to a green hemat-fruit, which is hard and cool under thy hand, like
touching those swellings which are on his breast.
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Case 39 in the papyrus describes a swelling over the breast with pus and redness,
which felt hot to the touch. It is obvious that the author of the papyrus is making a
distinction between this (an infected wound or abscess resulting from an injury) and
Case 45, which did not apparently result from an injury.
It is perhaps not surprising that the first apparent case of male breast cancer was
reported from Egypt. In modern times, the incidence of male breast cancer in
comparison to female breast cancer in Egypt is relatively high. El-Gazayerli and
Abdel-Aziz (1963) report a consecutive series of 218 cases of breast carcinoma, of
which 14 (6-4%) were in males. The authors attribute this high relative incidence of
male breast cancer to hyperoestrogenism secondary to bilharzial (Schistosomal) liver
fibrosis. There is good evidence that bilharzia (Schistosomiasis) existed in ancient
Egypt. Calcified bilharzia ova have been demonstrated on microscopy of the kidneys
from mummies (Ruffer, 1910). Evidence of Schistosoma infestation has been
demonstrated in a predynastic (3200BC) mummy (Deelder et al, 1990).
1.2 Further Historical Records OfMale Breast Cancer
There are several reports of cancer of the male breast published in the Middle Ages
(Sasco et al, 1993). The renowned surgeon John of Arderne (c.1307 - c.1390)
described a priest who had a 2-year history of a slowly growing wound on the right
nipple. Other reports include those by Franciscus Arcaeus (1493-1573) and the father
of French Surgery, Ambroise Pare (1510-1590).
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2.1 Familial Male Breast Cancer
Male breast cancer is a rare disease, accounting for less than 1% of total cases of
breast cancer. It is estimated that in the year 2002, 1500 men in the United States will
have developed breast cancer, compared with 203500 women (Jemal et al, 2002).
Between 1989 and 1998, 156 cases ofmale breast cancer were registered in Scotland,
compared to 32182 cases of breast cancer in women (Scottish Health Statistics,
2001). In other words, 0-48 % of cases of breast cancer registered during this period
in Scotland, were in men.
Because of the rarity of male breast cancer, most reported series involve relatively
small numbers of cases. Less is therefore known about the potential genetic
influences in its development than for female breast cancer.
The possibility of a familial component to the aetiology of male breast cancer has
been recognized for many years. In 1889, Williams gave a record of 100 cases of
cancer of the male breast. Inquiries about family history had been made in 29 of
these cases, and there was a history of cancer in seven families. In one of these
families, the patient's father was said to have had breast cancer, although no further
details are given as to whether this was verified. In two of the families, the patient's
sister had breast cancer and in another family a maternal aunt was affected.
In 1926, Judd and Morse described 17 cases of male breast cancer presenting to the
Mayo Foundation. The mother of one of these cases died with carcinoma of the
breast and three other cases gave a family history of cancer.
Schottenfeld et al (1963) reviewed 120 male breast cancer patients treated throughout
the U.S. between 1955 and 1962. 53 of these patients were interviewed and two
reported breast cancer in another male family member.
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Marger et al (1975) reported the first well-documented cases of breast cancer
occurring in male relatives. These authors reported 30 cases ofmale breast cancer
presenting to a single hospital over a 50-year period. Two of the cases, aged 52 and
69 at the time of diagnosis, were brothers. The elder of the two had also been
diagnosed with adenocarcinoma of the prostate three years previously and had been
treated with oestrogen. The sister of another of the cases had bilateral breast cancer.
At the time of this publication, it was already known that the risk of breast cancer in
a woman was increased if her mother had been affected. The authors suggested that it
might be worthwhile looking at the incidence of breast cancer in women with
affected fathers, to see if an increased risk was conferred to them in this manner.
In 1976, Everson et al described the occurrence ofmale breast cancer in two
families. In one family, three brothers and four female relatives on the maternal side
had breast cancer. In the other family, the proband, his father and a paternal uncle
had breast cancer. Within both of these families there was no consanguinity and there
was nothing to suggest occupational exposure to any possible aetiological agents.
The occurrence of breast cancer in both males and females within one family, led the
authors to suggest that familial susceptibility to breast cancer can occur regardless of
gender. Increased urinary excretion of oestrogen was found in one of the males with
breast cancer and also two unaffected male relatives of cases. It was therefore
suggested that in these patients there might have been an abnormality in oestrogen
production or metabolism.
Teasdale et al (1976), report a male who developed breast cancer aged 59 and gastric
cancer aged 66. His brother developed breast cancer aged 70, and his daughter aged
only 26. It was suggested that paternal genetic factors may have increased the
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susceptibility of the proband's daughter to breast cancer. Interestingly, a sister of the
proband had ovarian cancer and another brother had oral cancer.
Several more recent studies have now demonstrated, and attempted to quantify, an
increased risk of breast cancer among female relatives of breast cancer cases, with a
relative risk varying between two and sixteen times the population risk (Anderson &
Badzioch, 1992; Storm & Olsen 1999).
While familial male breast cancer has been recognized for more than a hundred
years, it is only within the last decade that responsible genetic factors have been
postulated. These are discussed below.
2.2 Androgen Receptor Gene
The first report of a germline genetic mutation linked to male breast cancer was in
the androgen receptor gene within codon 607 (Wooster et al, 1992). This mutation
was found in two brothers who both had androgen insensitivity and developed breast
cancer aged 55 and 75 years. It was thought possible that the development of breast
cancer in these men may have been due to abnormal stimulation of the breast
epithelium, with loss of the protective effect of androgens. Alternatively, the
androgen receptor gene mutation itselfmay have had specific biological effects that
increased breast cancer risk. Another mutation in the androgen receptor gene within
codon 608 has since been reported in an isolated male with breast cancer and partial
androgen insensitivity (Lobaccaro et al, 1993). This mutation resulted in an amino
acid substitution adjacent to the first reported mutation, suggesting that the
association between male breast cancer and mutations in the androgen receptor gene
is not purely coincidental. On the other hand, Haraldsson et al (1998) in a study of 34
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male breast cancer cases from Sweden, found no evidence of germline or somatic
androgen receptor gene mutations.
Another study also failed to identify any somatic mutations within the androgen
receptor gene in breast cancers (Shan et al, 2000). However, somatic reductions in
the length of a CAG repeat sequence within the androgen receptor gene have been
found in colonic cancers (Ferro et al, 2000).
2.3 BRCA1
The breast cancer susceptibility gene BRCA1 was mapped to chromosome 17q (Hall
et al, 1990 & Narod et al, 1991). It was cloned in 1994 (Miki et al). Familial and
early onset female breast cancer have been linked to mutations in the BRCA1 gene
(Futreal et al, 1994; Castilla et al, 1994; Friedman et al, 1994; Gayther et al, 1995).
However, subsequent studies described below suggest that the association between
BRCA1 mutations and male breast cancer is much less strong.
Stratton et al (1994) reported a study of 22 families, all with at least one case ofmale
breast cancer. In this study, linkage analysis was performed and it was estimated that
0% (95% C.I. 0% to 18%) of the families were linked to BRCA1. The authors
suggested that probably only a small proportion of breast cancer families containing
a male case are linked to BRCA1, and that there is another gene associated with a
higher risk ofmale breast cancer. In a large study of 54 male breast cancer cases
from Southern California (Friedman et al, 1997), no mutations were found in
BRCA1.
Isolated cases ofmale breast cancer have, however, been reported in carriers of
BRCA1 mutations. Hogervorst et al (1995) detected a BRCA1 mutation within a
9
family containing a male breast cancer case, however no DNA was available from
the affected male for testing. Struewing et al (1995) studied 24 families, each with at
least one case of ovarian cancer and a total of at least three cases of breast and
ovarian cancer. Eight BRCA1 mutations were detected in ten families. One of these
families contained a male affected by breast and prostate cancer, who was found to
carry a BRCA1 mutation. In a large study of 237 families, Ford et al (1998) found
BRCA1 mutations in two families from 14 screened, that contained a case ofmale
breast cancer. However, it was not stated whether the affected males themselves, or
just other affected female family members were screened. In another large study
from Israel, a BRCA1 founder mutation was detected in four males with breast
cancer, out of 124 males that were screened (Struewing et al, 1999). However,
approximately 1% of the Ashkenazi Jewish population as a whole are carriers of this
mutation (Fodor et al, 1998).
2.4 BRCA2
In 1994, Wooster et al localized the BRCA2 gene to chromosome 13q. This study
included six families containing cases ofmale breast cancer. A study from Iceland
(Thorlacius et al, 1995) linked a family with four cases ofmale breast cancer to the
BRCA2 gene. The BRCA2 gene has subsequently been identified (Wooster et al
1995). It is made up of 27 exons (the first ofwhich is non-coding) and it encodes a
protein made up of 3418 amino acids (Tavtigian et al, 1996).
Several possible functions ofBRCA2 have been suggested. BRCA2 may have a role
in the regulation of transcription, and certainly, one study has demonstrated that the
BRCA2 protein could stimulate transcription (Milner et al, 1997).
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Experimental studies in mice have shown that cells without a functional BRCA2
gene, when subjected to irradiation, fail to efficiently repair double-strand DNA
breaks (Connor et al, 1997). In cells that do not have a functioning BRCA2 gene,
there is a spontaneous instability of chromosome structure and abnormalities of
chromosome number (Patel et al, 1998). Many of the chromosomal abnormalities
develop during DNA replication. Non-homologous repair ofDNA breaks (by simply
joining the broken ends ofDNA) can occur without a functional BRCA2 gene.
However this type of repair is prone to inducing errors at the site of repair (Yu et al,
2000). A role for BRCA2 in the homology-directed repair of double-strand breaks in
DNA has been demonstrated (Moynahan et al, 2001). In other words, BRCA2-
deficient cells are unable to repair DNA by homologous recombination, which
involves exchanging the broken DNA for a perfect copy, and is therefore error-free.
The consequence is that there is increased chromosomal instability within these cells.
Homologous recombination involves a protein called RAD51 that is involved in the
repair of double-strand breaks in DNA and also in mitotic and meiotic recombination
(Sharan et al, 1997). The BRCA2 protein sequence contains eight repetitive units
known as BRC motifs (Bork et al, 1996; Bignell et al, 1997). Binding sites for
RAD51 have been mapped to the BRC motifs in BRCA2 (Wong et al, 1997; Chen et
al, 1998). This suggests that BRCA2 regulates homologous recombination through
its interaction with RAD51 (Venkitaraman, 2002). More recent structural studies
have shown that a small molecule called Dssl binds to the carboxy-terminal end of
BRCA2 (Yang et al, 2002). The BRCA2-Dssl complex can bind to single- and
double-stranded DNA. The ability of this complex to bind to DNA suggests that
BRCA2 may carry RAD51 to sites ofDNA damage, ultimately leading to DNA
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repair (Venkitaraman, 2003). It has also been shown that polymorphisms in RAD51
increase the risk of breast cancer among carriers of BRCA2 mutations (Levy-Lahad
et al, 2001; Wang et al, 2001).
Wooster et al (1995) also reported the first BRCA2 mutations to be found in male
breast cancer cases. The published detected frequency ofBRCA2 mutations among
groups of male breast cancer patients varies considerably between different
populations. In a series of 54 male breast cancer cases from Southern California, only
two (4%) were found to have germline BRCA2 mutations (Friedman et al, 1997).
This contrasts with the 13 cases from a series of 34 (38%) in Iceland (Thorlacius et
al, 1998). However, all of these 13 cases carried a single founder BRCA2 mutation
thought to originate from a single common ancestor at least 500 years ago.
There have now been many published series including male breast cancer cases in
which BRCA2 mutations have been detected (Table 2-1).
In addition to male and female breast cancer, germline mutations in BRCA2 are well
described in familial ovarian carcinoma (Wooster et al, 1995; Tavtigian et al, 1996;
Easton et al, 1997; Schubert et al, 1997; Gayther et al, 1997). They have also been
found, albeit more infrequently, in sporadic ovarian carcinomas (Takahashi et al,
1996). Germline BRCA2 mutations have also been associated with a variety of other
cancers, including prostate (Easton et al, 1997; Struewing et al, 1997; Breast Cancer
Linkage Consortium, 1999; Gayther et al, 2000) and pancreas (Phelan et al, 1996;
Goggins et al, 1996; Breast Cancer Linkage Consortium, 1999; Gronberg et al, 2001;
Murphy et al, 2002).
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Table 21
Published series including male breast cancer cases in which BRCA2 mutations have
been detected
Series Country No. MBC Cases
No. BRCA2
Mutations
Couch et al (1996) U.S.A. 50 7 (14%)
Friedman et al (1997) U.S.A. 54 2 (4%)
Mavraki et al (1997) England 28 3 (11%)
Thorlacius et al (1998) Iceland 34 13 (38%)
Haraldsson et al (1998) Sweden 34 7 (21%)
Csokay et al (1999) Hungary 18 6 (33%)
Struewing et al (1999) Israel 124 15 (12%)
Diez et al (2000) Spain 17 3 (18%)
Wolpert et al (2000) Canada 14 2 (14%)
Kwiatkowska et al (2001) Poland 37 4(11%)
Pages et al (2001) France 12 4 (33%)
Basham et al (2002) England 94 5 (5%)
Ottini et al (2003) Italy 25 3 (12%)
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Whilst gennline mutations in BRCA2 are well described, somatic BRCA2 mutations
in breast and ovarian carcinomas are relatively rare (Lancaster et al, 1996; Miki et al,
1996; Takahashi et al, 1996; Weber et al, 1996; Foster et al, 1996). There is only one
report in which a somatic BRCA2 mutation was detected in a single male breast
cancer case (Kwiatkowska et al, 2002).
2.5 Other Genes
Germline p53 mutations have been reported in a few cases of female breast cancer
associated with Li-Fraumeni syndrome (Rapakko et al, 2001). To date there are no
reports of germline p53 mutations in male breast cancer cases. However, somatic p53
mutations are common in carcinomas of the male breast (Anelli et al, 1995).
A germline mutation of the MLH1 mismatch repair gene has been described in a
male who developed colonic carcinoma aged 41 and breast cancer aged 72 (Boyd et
al, 1999). He was a member of a hereditary non-polyposis colorectal cancer
(HNPCC) family. Another study (Borg et al, 2000) describes two HNPCC families
that include male and female breast cancer cases. Both had germline mutations in
MLH1, but one male also had a mutation in BRCA1.
Cowden syndrome is associated with mutations in the PTEN (phosphatase and tensin
homologue mutated on chromosome ten) tumour suppressor gene. A recent study
describes gennline mutations in the PTEN gene in two families containing cases of
male and female breast cancer (Fackenthal et al, 2001).
The gene CHEK2 (otherwise known as CHK2) codes for a kinase that is activated as
a response to DNA damage (Matsuoka et al, 1998; Chaturvedi et al, 1999). Germline
CHEK2 variants have previously been reported in Li-Fraumeni families where no
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p53 mutations were found (Bell et al, 1999). In one recent study (Meijers-Heijboer et
al, 2002), a variant in CHEK2 (1 lOOdelC) was found in 55 out of 1071 (5.1%)
families with breast cancer in whom no BRCA1 or BRCA2 mutations had been
found. This was a higher than the 1.1% of healthy controls found to carry the
CHEK2 variant. This study also found the variant in 7 out of 52 (13.5%) families that
contained at least one case of male breast cancer. The authors concluded that within
BRCA1 and BRCA2 negative families, this variant gave a relative risk for female
breast cancer of approximately two and for male breast cancer, an approximately ten
times increase in risk. A subsequent study has also reported an association between
the CHEK2 1 lOOdelC variant and familial female breast cancer (Vahteristo et al,
2002).
Mutations of the genes discussed above clearly confer a greatly increased risk of
breast cancer on a carrier. However, the frequency of such genetic mutations within
whole populations is relatively small. A recent meta-analysis showed an increased
relative risk of breast cancer of 2-3 (95% confidence interval 1 -6-3-2) associated with
high levels of oestrogens in post-menopausal women (Key and Verkasalo, 1999).
Male breast cancer is also known to be associated with increased levels of serum
oestrogens, for example, in Klinefelter's syndrome (Jackson et al 1965). Any genetic
changes that may result in elevation of the level of oestrogens may therefore result in
an increased risk of developing breast cancer. The risk to an individual conferred by
high oestrogen levels is estimated at 2-3 times greater than the general population
risk (as indicated above). The risk of female breast cancer in the Scottish population
as a whole is reported to be 7-9% to the age of 74 (Cancer Registration Statistics
Scotland 1986 - 1995). The risk to those individuals with high oestrogen levels
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would therefore be approximately 18%. This is lower than the cumulative risk to age
70 associated with carriage of a BRCA1 or BRCA2 mutation, which is estimated to
be between 26% and 56% by population-based studies (Satagopan et al, 2001;
Struewing et al, 1997). However, in general population terms, oestrogens are likely
to be important, given that the carriage of a germline mutation is rare.
The pathway for synthesis of androgens and oestrogens is shown in Figure 2*1.
Figure 2*1











(Adapted from Ganong, 1993)
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The CYP17 gene on chromosome 10 codes for the Cytochrome P450cl7 enzyme
that catalyses steroid 17a-hydroxylase and 17,20-lyase activities (Picado-Leonard,
1987). It is therefore a key regulator in the synthesis of androgens and oestrogens
from their steroid precursors (Brentano et al, 1990).
A polymorphic T —> C substitution has been described that creates an additional
CCACC type promoter site 34bp upstream from the site of initiation of translation
(Carey et al, 1994). It is thought that the additional promoter site may increase the
rate of transcription of the gene and thereby increase enzyme activity. This
polymorphism also generates a restriction site for the enzyme MspAl. Serum
oestradiol levels are higher in women hetero- and homozygous for the C allele of the
CYP17 gene (Feigelson et ah 1998). One study found that the C allele was associated
with an increased risk of advanced breast cancer (Feigelson et al, 1997). A larger and
more recent study, however, found no such association (Dunning et al, 1998). Given
that the C allele of the CYP17 gene is associated with increased serum oestradiol
levels, then it could also be implicated in the development of male breast cancer. The
association with advanced breast cancer in females may also be relevant to males,
given that men with breast cancer tend to present with more advanced disease than
women (Ravandi-Kashani & Hayes, 1998).
The CYP19 gene (located on chromosome 15q21.1) codes for the aromatase enzyme
that controls the rate limiting step in the pathway of oestrogen synthesis from steroid
precursors (Figure 2-1). As already stated, it is known that an increased risk of breast
cancer in males is associated with elevated serum oestrogen levels. The aromatase
enzyme has been observed within the stromal cells in a greater proportion of male
17
breast carcinomas than gynaecomastia cases, suggesting that locally produced
oestrogens may also have a significant role in the development ofmale breast cancer
(Sasano et al, 1996). It is therefore possible that variation in expression of the CYP19
gene could affect the risk of developing male breast cancer.
A polymorphic tetranucleotide (TTTA) repeat sequence is found in intron 5 of the
CYP19 gene, 79 nucleotides downstream from exon 4 (Means et al, 1989). This
repeat sequence is relatively close to the exon / intron border and may therefore be
involved in the determination of splicing sites (Kristensen et al, 1998).
A region within exon 1 of the gene coding for the androgen receptor (located on
chromosome Xql 1 -12) is highly polymorphic and contains a variable number of
CAG repeats. The variability of the number of these repeats between different ethnic
populations in the U.S. has been studied (Edwards et al, 1992). In vitro studies have
shown that a relatively short CAG repeat sequence increases the level of
transactivation of the androgen receptor (Chamberlain et al, 1994). The androgen
receptor itself binds dihydrotestosterone and therefore is one factor in the regulation
of the growth of prostate cells. This may account for the finding that short CAG
repeat sequences have been associated with a higher risk of developing prostate
cancer (Stanford et al, 1997; Giovannucci et al, 1997). Abnormally long sequences of
40 repeats or more are found in patients with X-linked spinal and bulbar muscular
atrophy, otherwise known as Kennedy's disease (LaSpada et al, 1991). This disease
is associated with gynaecomastia and reduced fertility, indicating androgen
insensitivity. Mutations of the androgen receptor gene, found in a few cases ofmale
breast cancer as described above, may also result in reduced androgen receptor
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function. It is therefore possible that long CAG repeat sequences in the androgen
receptor gene are associated with an increased risk ofmale breast cancer.
The human oestrogen receptor (ESR1) gene is located on chromosome 6q24-q27.
Other published studies have looked at polymorphisms in the oestrogen receptor
gene, but have not shown a consistent association with female breast cancer
(Andersen et al, 1994; Schubert et al, 1999; Yaich et al, 1992). One of these
polymorphisms is a T—>C substitution in Intron 1. This single-base change results in
loss of a restriction site for the enzyme PvuII. Another of the polymorphisms in the
oestrogen receptor gene is a G—>C substitution in Exon 2. This generates a restriction
site for the enzyme BstUI.
2.6 Hypotheses And Aims Of The Study
The original hypotheses prior to commencing the study were :
1. BRCA2 mutations might be commoner among male breast cancer cases in
Scotland than elsewhere in UK.
2. There might be founder BRCA2 mutations in Scotland.
3. There might be an excess of other cancers among the male breast cancer cases
and their relatives.
4. A polymorphism in the CYP17 gene might increase the risk ofmale breast
cancer.
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The aims of the study were as follows :
1. To screen a large series ofmale breast cancer patients for mutations in the
BRCA2 gene.
2. To construct detailed family pedigrees for these patients, and hence to
evaluate male breast cancer as a risk factor for female breast cancer in
relatives.
3. To determine whether or not the clinical outcome is different for male breast
cancer that is associated with BRCA2 mutations.
4. To establish whether the C allele of the CYP17 gene is associated with an
increased risk of male breast cancer.
5. To determine whether the development of male breast cancer is influenced by
the length of a tetranucleotide repeat sequence in the CYP19 gene.
6. To investigate whether increased length of the CAG repeat sequence in the
androgen receptor gene is associated with the development ofmale breast
cancer.
7. To investigate the frequencies of two oestrogen receptor gene polymorphisms
in male breast cancer cases.
Note : The aims numbered 5 to 7 were only conceived after the study commenced
and were therefore not part of the original hypothesis.
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3.1 Polymerase Chain Reaction
The Polymerase Chain Reaction (PCR) is an in vitro method for the amplification of
a segment ofDNA (Mullis et al, 1986). This allows an adequate quantity of a
specific sequence ofDNA to be produced for screening to identify mutations and
polymorphisms. Changes in temperature are needed for this in vitro reaction to
occur. Firstly, by heating to about 94°C, the bonds holding the strands together can
be broken so that the DNA is single-stranded. The temperature of the reaction is then
dropped to between 50 and 60°C. Two oligonucleotide primers can then hybridise to
complimentary strands of the DNA, flanking the region of interest. The new DNA is
synthesised on to the 3'-end of the two primers by a heat-stable DNA polymerase,
usually at 72°C. This process is then repeated. In theory, the amount of specific
sequence DNA doubles each cycle. In reality, if the reaction is performed 30 times,
then about 105 copies of the specific sequence should be made (Strachan & Read,
1997). This process would take only a few hours. The process of temperature cycling
is automated using thermocyclers, which are sophisticated programmable hot blocks.
Screening of genomic DNA for mutations can be performed once adequate quantities
of the specific sequence to be studied have been produced by PCR. The gold-
standard method of identifying mutations is DNA sequencing. However this is very
expensive if entire genes are to be screened. Methods that detect possible sequence
changes, and allow targeted sequencing are therefore much more cost-effective. The




Formation ofDNA complexes called heteroduplexes can occur when two DNA
strands that differ in their sequence anneal together. This was first described by
Nagamine et al (1989). In this study, one of the strands contained a deletion of 18
bases. It was hypothesised that either the strands might be annealed with the extra 18
bases on one strand forming a bulge, or the strands might only be annealed on the 3'
side of the deletion. The consequential difference in secondary structure resulted in
abnormal migration of the heteroduplex structure through a polyacrylamide gel. It
has since been suggested that a more marked conformational change in the structure
of the DNA, a bend, would produce a greater difference in migration between a
homoduplex structure and a heteroduplex one (Ganguly et al, 1993). Another study
showed that a smaller deletion of 3-bp in the cystic fibrosis gene could also be
detected using this method (Rommens et al, 1990). However, it is possible to detect
even more subtle genetic alterations, i.e. single base pair substitutions, by the process
of heteroduplex analysis (HA) (Keen et al, 1991). The appearance of heteroduplexes
after electrophoresis on a gel are illustrated in Figure 3-1.
HA has been shown to be a sensitive technique in the detection of single base-pair
substitutions. In one study, eight out of nine (89%) single base substitutions were
detected (White et al, 1992). The overall sensitivity ofHA in detecting sequence
changes has been reported as low as 60% (Choy et al, 1999), but in other studies as
high as 92% (Korkko et al, 2002) and 100% (Korkko et al, 1998). The specificity of
HA is uniformly reported to be 100%. Any errors within the screening process are
most likely to arise during PCR rather than the subsequent analysis ofPCR products.
The advantages ofHA are that it is a relatively simple process, there is no need for
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specialist equipment or special preparation of the PCR product and it is not necessary
to use radioactivity in order to visualise the bands on the gel. The limitations ofHA
for mutation detection include the requirement for subsequent sequencing of PCR
products found to contain abnormalities, a large number ofwhich may be
insignificant polymorphisms. HA also gives no indication as to the position of the
sequence change within the PCR product. The length of the PCR product under study
appears to be important and is one of the factors that affect the sensitivity ofHA. It
has been shown that the optimal length of the PCR product should be between 150
and 200bp (Ganguly et al, 2002).
An alternative method of screening PCR products for sequence changes is single-
strand conformation polymorphism (SSCP). This process depends upon the single
strands of denatured DNA forming different conformations if their sequences differ.
The sensitivity of SSCP appears to be highly dependent upon the size of the DNA
fragments analysed. For fragments of 150-212bp in size, the sensitivity for detection
of single base substitutions in one study was 79% (Sheffield et al, 1993). In this
study, sensitivity was lower for larger fragments and for fragments less than 150bp in
length. Several studies have compared heteroduplex analysis directly with SSCP. In
one study, SSCP detected only seven of the eleven mutations detected by HA
(Henderson et al, 1997). However, in another direct comparison between the two
methods the sensitivity was similar, 85% for SSCP and 82% for HA (Jones et al,
1999). In another study (Rosetti et al, 1995), the sensitivity for HA was found to be
81% and SSCP 69%. Importantly however, for fragments between 257 and 426bp in
length, the sensitivity ofHA was 100%, but SSCP only 20%. For the screening of
BRCA2 in our study, 44 of the 62 primer pairs produce PCR products within this
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size range. Using this set of primers, HA is therefore likely to be a more sensitive
method of screening than SSCP.
Figure 3-1
An illustration of the appearance of heteroduplexes after electrophoresis on a gel
Wild-type Homozygote Mutant Heterozygote
(single base substitution G-»A on one allele)
HA is an effective method of screening a group of samples for a single mutation,
however if the entire coding sequence of a gene is screened, then the process can be
laborious. Several different areas of the gene can be screened at once, if the PCR
products are of different length, by use of a multiplex analysis (Gayther et al, 1996).
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Recently, more rapid automated methods of performing HA have been developed
(Tian et al, 2000; Edwards et al, 2001).
3.3 Protein Truncation Testing
Just over 50% of reported mutations in BRCA2 are frameshift or non-sense (Breast
Cancer Information Core), and therefore might be expected to result in premature
termination of translation and consequent truncation of the protein product. Some
techniques that have been used to detect DNA sequence changes (such as HA,
described above) may identify polymorphisms and mis-sense sequence changes
which are of doubtful significance. A technique that is able to detect mutations that
result in a truncated protein product alone would therefore be a valuable tool, if rapid
screening of a gene were required. While avoiding the detection of possibly
meaningless mis-sense changes, this method may however fail to detect truncating
mutations at either end of the exon (Davies et al, 2000).
Such a technique, known as the protein truncation test (PTT), was initially developed
to screen the Duchenne Muscular Dystrophy (DMD) gene (Roest et al, 1993) and the
APC gene (Powell et al, 1993; van der Luijt et al, 1994). More recently, PTT has
been used for the detection ofmutations in BRCA1 (Hogervorst et al, 1995;
Plummer et al, 1995) and BRCA2 (Garvin, 1998).
The coding region of a gene is screened for mutations that result in premature
termination of translation, using protein that is synthesised in vitro. First, an
amplified DNA product corresponding to the coding sequence of the gene to be
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studied is obtained. This is done either by PCR amplification of genomic DNA, or by
reverse transcription PCR (RT-PCR) amplification ofmRNA.
For each PCR used during PTT, a special sense / forward primer with an additional
'tail' is designed (Hogervorst, 1997). This primer contains four regions, three of
which form the 'tail'. Firstly, a T7 promoter sequence is at the 5'-end of the primer.
This directs the production ofRNA using an RNA Polymerase. There is then a
spacer sequence of 3-6bp in length. Next is a eukaryotic translation initiation
sequence, otherwise known as the Kozak sequence (Kozak, 1984). The 3'-end of the
primer contains the target gene sequence (approximately 17-20bp in length). A
restriction site sequence is sometimes incorporated into the 5 '-end of the primer. This
allows cloning of the amplified product. PTT primers previously used for screening
of exons 10,11 and 27 of BRCA2 (Lancaster et al, 1996) contained the T7/Kozak
sequence shown in Figure 3-2.
The DNA sequence of the tailed forward primer clearly is not identical to the
sequence of the genomic DNA under study and there may therefore be problems in
terms of the primer not annealing. In order to overcome this potential problem and to
increase the yield of PCR product, nested PCR can be performed. This involves an
initial PCR amplification of the genomic DNA using standard primers. A secondary
PCR reaction is then performed using the PTT primer as the forward primer and the
primary PCR product as the DNA template.
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Figure 3-2
Components of the forward primer used for PTT
5'- GGATCCTAATACGACTCACTATAGGGAGACCACCATG -3'
I I I I I I I I 1 I
R 1 2 3 4
R Restriction Site Sequence 1
2 Spacer 3
4 Target gene sequence
Bacteriophage Promoter T7 Sequence
Kozak Sequence
The PCR products that are produced are checked by electrophoresis on agarose gels.
If products of abnormal size are seen, then this can indicate the presence of deletions
or duplications. IfmRNA has been used, then mutations within splicing sites may
result in a PCR product of abnormal length. The PCR products are then used for the
in vitro synthesis ofRNA. This RNA is then translated into protein. This process of
in vitro transcription followed by translation, has been greatly simplified by
development of the TnT© Quick Coupled Transcription/Translation System
(Promega).
In order to determine whether or not a truncated protein product has been
synthesised, the proteins need to be separated, according to their size, by
electrophoresis. The disulphide bridges in proteins need to be reduced before they
can adopt the necessary configuration to allow separation by electrophoresis. This
can be done using [3-mercaptoethanol (Strachan & Read, 1997). Sodium dodecyl
sulphate (SDS) binds to proteins and gives them a negative charge. The proteins
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undergo denaturing SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE). The
distance that the proteins migrate down the gel is inversely related to their molecular
weight.
The proteins can be visualised by the incorporation of radio-labelled amino acids
when they are being synthesised. Non-radioactive methods of protein detection have
TM
been developed, for example the Transcend Colorimetric Translation Detection
System (Promega). This involves the incorporation of biotinylated lysine residues
into the protein. The biotinylated proteins can be visualised by binding Streptavidin-
Alkaline Phosphatase followed by Western Blue® Substrate to produce coloured
bands.
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Ethical approval for the study was obtained from the Lothian Regional Ethics
committee.
4.1 Male Breast Cancer Cases
The initial basis for our study came from a clinical review that had been performed
of 55 male breast cancer patients treated in the Department ofClinical Oncology,
Western General Hospital, Edinburgh between 1974 and 1993 (Andrews et al, 1996).
This list of 55 cases was updated to include those treated between 1994 and 1998.
There were then a total of 76 male breast cancer patients, treated over a 25-year
period. A summary of how DNA samples were obtained from the male breast cancer
cases is shown in Figure 4-1.
26 of the 76 male breast cancer cases were alive in 1998. Contact was made by
telephone with the General Practitioners of these patients to discuss the study. In
each case, permission was sought from them to approach the patient concerned.
Initial contact was then made with the patient by telephone, or by letter if this was
not possible. An interview with each patient was then arranged. Only two patients
declined to take part in the study. The study was discussed with the patient and
written consent was obtained. A detailed family history was then taken from each
patient and recorded on the form shown in Appendix 7T. 10ml peripheral blood
samples were obtained from each of the patients in four 2-5ml tubes containing
EDTA and frozen at -70°C as soon as possible thereafter.
For the deceased patients, details of the hospital where a biopsy was taken or surgical
treatment was performed were obtained from the hospital casenotes (stored in the
Department ofClinical Oncology). Pathology specimen numbers were retrieved
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where recorded. A pathologist in the hospital concerned was then contacted and
archival wax-embedded tissue sections were obtained where possible. Archival tissue
samples were obtained for 39 deceased patients, as detailed in Figure 4-1. No
specimens obtained at post-mortem examination were used. DNA previously
extracted from a blood sample and stored was available for one of the deceased
patients. Archival specimens were not available in 10 cases.
For analysis of a polymorphism in the CYP17 gene, female breast cancer cases were
also required. These were from blood samples taken from a consecutive group of 39
patients with early onset (age <50 years) breast cancer referred to the Edinburgh
Breast Unit, Western General Hospital, Edinburgh between 1987 and 1990.
4.2 Control Population Selection
Male and female control DNA samples were extracted from blood donations to the
Edinburgh and South East Scotland Blood Transfusion service (82 samples), from
placental tissue and blood donations to the School of Biological and Medical
Sciences, University of St. Andrews (49 samples), and from tonsillectomy specimens
provided by the Department ofE.N.T. Surgery, City Hospital, Edinburgh (8
samples). In order to ensure confidentiality, the only information that we were given
about the original donors was their gender. These controls were not matched for age
with the cases, however the majority were from blood donors, thereby including
healthy members of the general population between the ages of 17 and 70. We
believe that these samples were as representative of the population within South East
















For all Scottish-born patients (living or deceased) a complete family tree extending
for at least three generations on both maternal and paternal sides was constructed.
This was performed by an experienced genealogist (Alison Fordyce) by examining
the Scottish public records of births, deaths and marriages (held by the Registrar
General for Scotland). The use of the Scottish Public Records in similar situations is
described by Collyer and DeMey (1987). In Scotland, the actual records of births,
deaths and marriages can be viewed directly. In England, a record has to be
purchased before it can be viewed. For this reason, and because of the larger
population of England, it is much easier to construct pedigrees in Scotland.
The information and statistics division (ISD) of the Scottish NHS Common Services
Agency is responsible for the statistical analysis of all health service records. Their
databases include all hospital discharge records and population based cancer
registers. The cancer registration system includes cases confirmed histologically
(approximately 80%) and has data of good quality from 1968 to date. The names and
dates of birth of relatives (parents, grandparents, siblings, uncles, aunts and cousins)
of the male breast cancer cases were extracted from the pedigrees. The Scottish
Cancer Registry was examined to see if any of these individuals had a diagnosis of
fatal or non-fatal cancer. For reasons of confidentiality, the Cancer Registry would
only provide such information on relatives who are now deceased. For the male
breast cancer cases who were deceased prior to May 2002, dates of death were
provided by the cancer registry.
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4.4 Clinical Data
Clinical data for the patients were retrieved from hospital case records. Details for
each male breast cancer case in terms of age at diagnosis, disease stage at
presentation, histological type, and loco-regional disease recurrence were recorded.
For survival, the length of time between date of diagnosis (obtained from the case
records) and either the date of death (from the cancer registry data), or May 2002 (if
the patient is still alive) was calculated. The patients subsequently found to have
germline mutations in BRCA2 were grouped together and compared to those not
found to carry mutations. The clinical data were then analysed with the help of a
statistician (Gill Kerr).
4.5 DNA Extraction From Whole Blood
Within a Class I microbiological safety cabinet, 5mls ofwhole blood were lysed in a
50ml polypropylene centrifuge tube with 5mls of blood lysis buffer (0-1M Tris pH
8-0, 20mM NaCl, ImM Ethylenediaminetetraacetic acid (EDTA), 4% SDS). This
mixture was left at room temperature for 30 minutes. lOmls ofTE-saturated phenol
(phenol saturated with lOmM Tris, ImM EDTA) were then added. The tube was
centrifuged at lOOOg for 20 minutes.
In the class I cabinet, the upper layer was removed into a clean tube. 2-5mls 7-5M
ammonium acetate and 15mls cold isopropanol were added. The sample was mixed
and stored overnight at -20°C.
The following day, the tube was centrifuged at lOOOg for 30 minutes. The alcohol
was discarded, and the tube inverted to allow it to drain. 2-5mls de-ionised distilled
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water containing 1 -25mg Proteinase K was added. The tube was incubated at 48°C
overnight.
An equal volume of TE-saturated phenol was added. This was then mixed
thoroughly, and the sample centrifuged at lOOOg for 5 minutes. The upper layer was
removed into a clean tube. An equal volume of chloroform:iso-amyl alcohol (24:1)
was added, mixed thoroughly and the tube was then centrifuged at lOOOg for 5
minutes. The upper layer was removed into a clean tube. 0-125mls 7-5M ammonium
acetate and twice the volume of cold absolute ethanol were added. This was mixed
thoroughly and stored for 24 hours at -20°C.
The tube was centrifuged at 1 OOOg for 20 minutes, the alcohol removed and the tube
inverted to drain. The DNA was re-suspended in 250pl of distilled water.
In order to calculate the DNA concentration of this solution, lOpl of it was taken and
diluted further to a volume of lOOOpl. The optical density (OD) of this solution at
260nm was measured with a spectrophotometer. An OD=l is equivalent to a DNA
concentration of 50ng/pl, therefore the DNA concentration of the original solution
was calculated as follows :
DNA concentration (ng/pl) = OD260nm x 50 x 1000
10
An aliquot was then made to give a final concentration of 50ng/pl
The quality of the DNA was not specifically tested.
4.6 DNA Extraction From Paraffin Blocks
The method described below for extraction ofDNA from archival wax-embedded
tissue was modified from a method that has been described previously (Levi et al,
36
1991). This is a relatively rapid method ofDNA extraction that avoids the use of
xylene and ethanol, which remove paraffin from the sections. It can provide a good
yield ofDNA from a limited amount of tissue.
A 4pm section was cut from the paraffin block using a microtome. This was then
placed onto a microscope slide and dried at 60°C for 45 minutes. The slide was
stained with haematoxylin and eosin (see below).
The slide was then studied by a pathologist (Dr. K. Kurian) and the areas of tumour
(if present) and normal tissue in the section were identified and marked.
Between two and four (depending upon the area of tissue) 1 Opm sections were cut
from the paraffin block. If present, normal tissue was cut out for use. If no normal
tissue was present, then tumour tissue was used. The sections were then placed in
400pl XI lysis buffer (lOmM Tris, 50mM KC1, 0-45% Tween20, 2.5mM MgCh)
containing 0-5mg Proteinase K. This was incubated at 55°C for 6-8 hours. It was
then boiled for 20 minutes to denature the DNA and destroy the Proteinase K. lpl
0-5M EDTA was added. The solution was divided into 50-100pl aliquots. One of
these was stored at 4°C for immediate use and the remainder were stored at -20°C.
DNA concentrations were not measured.
4.7 Haematoxylin and Eosin Staining
The xylene, haematoxylin, eosin and different concentrations of ethanol used during
each part of the following process were in separate glass staining troughs.
Slides onto which paraffin sections had been dried were placed into a rack. The rack
was placed in xylene for 5 minutes to de-wax the sections. The slides were then
drained, placed in absolute ethanol for 1 minute followed by 70% ethanol for 1
37
minute and then 60% ethanol for 1 minute. The slides were rinsed in tap water for 2
minutes. The surface of the haematoxylin was skimmed with a paper towel in order
to remove oxidised particles. The slides were then placed into the haematoxylin for 5
minutes. The residual haematoxylin was rinsed offwith water and the slides were
dipped into 1% acid alcohol (1ml hydrochloric acid in 100ml absolute ethanol) for 5
seconds. They were rinsed with water for 1 minute, then placed in eosin for 30
seconds and rinsed with water for 1 minute. The slides were placed in 60% ethanol
for 1 minute, followed by 70% ethanol for 1 minute and then absolute ethanol for 1
minute.
If the staining appeared to be too dark, then the slides were placed in acid alcohol for
5 seconds. If the staining appeared too light, then the haematoxylin and eosin
staining was repeated.
The rack containing the slides was placed in xylene ready for mounting. DPX
synthetic resin mountant (a mixture of distyrene, a plasticizer and xylene)
was applied to a coverslip, the slide drained and then lowered onto the
coverslip. Any air bubbles between the slide and coverslip were then pressed
out.
4.8 Polymerase Chain Reaction (PCR)
Reaction mixtures were set up within a Class I microbiological safety cabinet in
order to minimise the risk of contamination. The constituents of the reaction mixture
depended on the primers used for each gene under study. These details are therefore
given later in the chapter in sections 4.15 - 4.19.
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All reactions were performed in 0-5 ml Eppendorf tubes and the mixture in each case
was overlaid with an equal volume (25 or 50pl) paraffin oil. With all sets of
reactions, a single tube containing no DNA was included in order to check for
contamination of the reaction constituents.
In all cases, a "hot-start' protocol was used. The principle of this is that the template
DNA and the primers are mixed together and held at a temperature above the
threshold of non-specific binding of primer to template, prior to addition of the Taq
DNA polymerase. Just before the cycling part of the reaction, polymerase is added to
allow the reaction to take place at higher temperature. The primers therefore do not
have the chance to anneal non-specifically to the template. Consequently, the
amplified DNA bands tend to be cleaner.
Using an OmniGene thermal cycler (Hybaid, UK) the initial denaturation step of the
PCR was performed at 94°C for 3 minutes. The tubes were then cooled down and
held at a temperature of 80°C. The Taq DNA polymerase was then inserted into each
tube (below the layer of oil) at this stage. The cycling process was then commenced.
In order to optimise the conditions for each PCR, DNA extracted from blood was
used. The concentration of certain constituents of the reaction were varied. The
concentration ofMgCb was varied between ImM and 2mM. The amount of each
primer used was varied between lOpmol and lOOpmol. The concentration of
deoxynucleoside triphosphates was varied between 1 OOpM and 200pM. The
annealing temperature for each reaction was initially based upon published data
where primers had been used in other studies, or the predicted annealing temperature
(Primer Designer vl.l ®1990 Educational Software) minus 5°C where primers were
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designed de novo. The annealing temperature was then lowered in 1 °C stages if the
PCR was unsuccessful, or raised in 1°C stages if there were too many non-specific
products.
It was found that some of the DNA samples extracted from paraffin sections did not
amplify well. In these cases, the PCR was repeated up to five times if necessary. The
volume ofDNA solution added was increased up to 5pl once the other conditions
had been optimised using samples containing higher concentrations ofDNA. It was
also found that lowering the annealing temperature by up to 5°C was helpful in some
cases.
4.9 Agarose Gel Electrophoresis
TBE buffer was prepared initially as a lOx stock, containing 0-89M Tris base, 089M
Boric acid and 20mM EDTA (pH8-0). lOOmls xl TBE buffer was added to 3g of
agarose powder in a conical flask. The mixture was heated in a microwave oven for a
total of 90 seconds, with mixing after 30 and 60 seconds. The molten agarose was
then allowed to cool to 60°C. 5pl ethidium bromide (lOpg/pl) was added and the
agarose poured into a slab gel mould. Combs were inserted and the gel was allowed
to set.
Once the gel had set, the combs were removed and the gel placed in a tank with xl
TBE buffer.
All PCR products were run on an agarose gel to confirm that the PCR had worked
successfully. 3 pi Xylene Cyanol/Bromophenol Blue loading buffer was mixed with
lOpl of each sample and loaded onto the gel. Electrophoresis was at 125volts for
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approximately 30 minutes. The gel was then visualised under ultraviolet light and if
the DNA had not run far enough down the gel, electrophoresis was continued.
4.10 Heteroduplex Analysis
A set of two glass plates was cleaned thoroughly with cream cleanser. The plates
were then rinsed thoroughly with tap water followed by 95% ethanol. They were
then dried with a paper towel. Prior to their first use, the shorter of the two plates was
marked "BIND' with a diamond-tipped pen and the longer plate was marked
'SLICK'.
In a Class I microbiological safety cabinet, silane solution (1ml 95% ethanol, 5pl
glacial acetic acid, 3pl y-Methacryloxypropyltrimethoxysilane) was applied
thoroughly to the 'BIND' plate. This plate was then wiped clean with 95% ethanol
four times using a fresh paper towel each time. With approximately every tenth use
of the plates, 3mls of gel slick were applied to the 'SLICK' plate after having
changed gloves. This was left for between five and ten minutes. The excess gel slick
was then wiped off with distilled water, and the plate dried with a paper towel. The
plates were assembled with 0-4mm spacers.
To make 50mls of non-denaturing lx Sequagel® MD gel, 25mls SequageP MD (2x)
was mixed with 7-5g urea, 3ml xlO TBE and 17-5mls ultrapure deionised distilled
water.
When ready for use, 400pl of 10% Ammonium Persulfate (APS) (not more than one
week old) and 40pl of Tetramethylethylenediamine (TEMED) were added. The gel
was then poured in between the plates using a 50ml syringe. A square tooth comb
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was placed in one end of the gel and secured with clamps. The gel was then allowed
to set for approximately one hour.
The plates were assembled vertically in S2 Sequencing gel apparatus (Life
Technologies^) and a total of 1 litre of 06x TBE poured into the upper and lower
chambers. The comb was removed and the gel wells were flushed out with 0-6x TBE
using a syringe.
The PCR products were denatured for 3 minutes at 95°C and then allowed to cool to
37°C over 30 minutes using a program on an OmniGene thermal cycler (Hybaid,
UK).
2 - 5pi of bromophenol blue loading buffer were added to 4-10pl of each sample and
these were then loaded onto the gel. A sample known to produce heteroduplexes was
also loaded as a control. Electrophoresis was for approximately 16 hours at 500 volts.
4.11 Silver Staining
The gel was placed into a litre of 10% ethanol (lOOmls absolute ethanol in 900mls
ultrapure deionised distilled water) and left on a rocking platform for 10 minutes.
The ethanol was then discarded and a litre 1% nitric acid (lOmls concentrated nitric
acid in 1 litre ultrapure deionised distilled water) was added. This was returned to the
rocking platform for 10 minutes. The plate was rinsed in ultrapure deionised distilled
water for 5 minutes and then 1 litre silver nitrate (2-04g in 1 litre ultrapure deionised
distilled water) was added. This was then left on the rocking platform for 20 minutes.
The silver nitrate was returned to its bottle and the gel was rinsed quickly (for 10
seconds) in distilled water.
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The plate was then rinsed in 1 litre of pre-cooled developer (160g sodium carbonate
decahydrate, lml formaldehyde, 2 litres ultrapure deionised distilled water, cooled
to 4°C). The developer was poured off when a precipitate developed and then
replaced with another litre of fresh developer. The gel was returned to the rocking
platform until bands appeared. The reaction was then stopped by adding 1 litre 0-1M
citric acid (19-2g in 1 litre ultrapure deionised distilled water). This was left for 10
minutes and the plate was then rinsed for 10 minutes in distilled water. The plate was




Sequencing was performed using Thermo Sequenase radiolabelled terminator cycle
sequencing kits (Amersham Life Science).
Sequencing of PCR products was usually performed in batches of six. 7pl of each
PCR product to be sequenced was taken and to this, lpl Exonuclease I and lpl
Shrimp Alkaline Phosphatase were added. The tubes (labelled 1 to 6) were heated to
37°C for 15 minutes, then to 80°C for 15 minutes.
24 0.5 ml Eppendorf tubes were taken and labelled G1 to G6, A1 to A6, T1 to T6 and
CI to C6.
These tubes were placed on ice. 12pl of dGTP nucleotide master mix was pipetted
into each of the tubes G6, A6, T6 and C6. 3pi of [a-33P]ddGTP was pipetted into
tube G6, 3pl of [a-33P]ddATP into tube A6, 3 pi of [a-33P]ddTTP into tube T6 and
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3pl of [a- PJddCTP into tube C6. 2-5pI of the mixture from tube G6 was transferred
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into each of the tubes G1 to G5. The same process was performed with the tubes A6,
T6 and C6.
The 6 cleaned PCR products were taken and to each tube, 2pl Reaction Buffer, 1 pi
Primer, lOpl DDW and finally 2pl Thermo Sequenase Polymerase were added. 4-5pl
of this reaction mixture from PCR tube 1 was transferred into each termination tube
(G1,A1,T1 and CI). The same process was performed for each of the remaining PCR
tubes 2 to 6. The contents of each of the 24 tubes were mixed well and overlaid with
20pl of oil.
The 24 tubes were then put onto an OmniGene thermal cycler (Hybaid, UK) and
cycled 38 times at 94°C for 45 seconds, Ta°C for 45 seconds and at 72°C 45 seconds
(where Ta was the annealing temperature used in the original PCR).
4pl STOP solution (95% formamide, lOmM EDTA pH8-0, 0-01% bromophenol blue,
0-01% xylene cyanol) was added to each of the termination reactions, they were
mixed thoroughly and then centrifuged briefly to separate from the oil.
Prior to use, the samples were heated to 95°C for 5 minutes and then cooled rapidly
on ice.
For each of the samples a 'long run' and a 'short run' was performed.
Electrophoresis was on a denaturing gel (see below) at 70 to 80 watts for 2-3 hours
('long run') and l-llA hours ('short run').
While still warm, the gel was transferred onto filter paper and then placed in a gel
drier. Within a darkroom, the dried gel was placed against the emulsion surface of an
autoradiography film, and the gel and film placed together into a light-proof cassette.
This was left overnight and the film was developed the following day.
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4.13 Denaturing Gel Electrophoresis
A 6% acrylamide stock solution was prepared by mixing 240g urea with 75mls 40%
acrylamide, 190ml deionised distilled water and 50ml lOx TBE for about 30-60
minutes using a magnetic stirrer.
If the gel was to be silver-stained, then the plates were prepared as described in the
previous section 'Heteroduplex Analysis' and assembled with 04mm spacers. For a
sequencing gel, a short plate free from bind solution was used.
For each gel, 75mls of the stock solution was taken and 500pl of 10% APS and 50pl
of TEMED were added.
The gel was poured in between the gel plates and a sharks-tooth comb inserted. The
comb was secured with clamps and the gel was allowed to set for 40-60 minutes.
The plates were assembled vertically in S2 Sequencing gel apparatus (Life
Technologies'") and 0-5x TBE poured into the top and bottom chambers (1 litre in
total was used). The comb was inverted and inserted until the teeth penetrated
approximately 2mm into the gel. The wells were flushed out with 0-5x TBE.
The gel was pre-run at 70watts to warm it for about 60 minutes.
While the gel was warming, the samples were prepared. 2-5pl of STOP solution was
put into the required number of tubes. 5pl of each sample was added to a tube. These
were heated to 95°C for 5 minutes and then cooled rapidly on ice.
The wells were flushed out again and 5pi of each sample loaded into the wells.
Electrophoresis was at 70watts until the xylene cyanol reached the bottom of the gel
(except when used for cycle sequencing - see above).
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4.14 Protein Truncation Testing (PTT)
Using primers selected from those used for amplification of the BRCA2 gene,
overlapping PCR products of 0.8-1.4 kb in size were generated, covering BRCA2
exons 10, 11 and 27. PTT forward primers described by Lancaster et al (1996) were
then used for nested PCR.
The TnT® Quick Coupled Transcription/Translation System (Promega) was used for
the in vitro generation of protein products from PCR amplified DNA. Reaction mixes
containing lOpl TnT® Quick Master Mix (Promega), 0.25pl ImM Methionine, 0.5pl
Transcend™ Biotin-Lysyl-tRNA and 2pl secondary PCR product were incubated at
30°C for 90 minutes.
A Mini-Protean® II Electrophoresis Cell (Biorad) was used for electrophoresis of the
samples. This allows two gels to be run simultaneously. Two sets of glass plates,
spacers and combs were assembled within a casting stand. A 12% polyacrylamide
gel mixture was made by mixing 4-1 mis deionised distilled water, 8mls 30%
acrylamide, 7-5mls 1M Tris pH 7-5, 200pl 10% SDS, 200pl 10% APS and 8pl
TEMED. The gel mixture was then poured between both sets of glass plates and left
to polymerise for 45-60 minutes. The combs were removed and the wells rinsed
thoroughly with distilled water. The electrophoresis cell containing the two gels was
then assembled. A 1 OX stock of SDS-PAGE running buffer was made by mixing 30g
Tris base, 144g glycine, lOOmls 10% SDS and deionised distilled water to a volume
of one litre. 300mls IX SDS-PAGE buffer was then prepared and used to fill the
chambers of the electrophoresis cell.
950pl loading dye was mixed with 50pl P-Mercaptoethanol. 20pl of this mixture was
then added to 12.5pl of each sample. 20pl loading dye was also added to 0.5pl ladder
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(Biotinylated SDS-PAGE Low Range Standard, Biorad). These samples were
denatured at 95°C for 3 minutes and then loaded onto the gels. Electrophoresis was
performed at 35mA for about 3 hours, until the dye had reached the bottom of the
gel.
The proteins were electroblotted onto nitrocellulose membranes using a Trans-Blot®
Electrophoretic Transfer Cell (Biorad). A 20X stock of transfer buffer was made by
mixing 29g glycine with 58g Tris, and making up to 500mls with deionised distilled
water. Just prior to use, 21 of buffer was made by mixing 1 OOmls of the 20X stock
solution with 400mls methanol and 1500 mis deionised distilled water. Nitrocellulose
membrane and filter paper were cut to the same size as the two gels. The membrane,
filter paper and fibre pads were soaked in the transfer buffer for 15 minutes. A fibre
pad was placed onto the Trans-Blot® cassette. A piece of filter paper was then placed
onto this, followed by the gel, then the membrane and then a second piece of filter
paper. Any air bubbles were removed and the second fibre pad placed on top. The
cassette was closed and placed into the tank, which was then filled with buffer. The
blotting was performed overnight at 25volts.
The proteins were then visualised using the Transcend"1 Colorimetric Translation
Detection System (Promega). After the blotting was completed, each wet membrane
was rinsed in tris-buffered saline (TBS), taking care to keep the side of the
membrane containing the proteins facing upwards. 15mls of TBS + 0-5% Tween®20
were added to the membrane left for 60 minutes at room temperature. 6pl
Streptavidin alkaline phosphatase (Streptavidin-AP) was diluted with 15mls fresh
TBS + 0.5% Tween®20. The previous solution of TBS + 0-5% Tween®20 was
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poured off and the Streptavidin-AP solution was added to the membrane. This was
placed on a rocking platform for a further 60 minutes. The Streptavidin-AP solution
was poured off and the membrane washed twice for one minute with 30mls TBS +
0-5% Tween®20, followed by two washes for one minute with 30mls TBS. The
membrane was incubated in about 5mls Western Blue® Stabilized Substrate for
Alkaline Phosphatase until the bands had reached the required intensity. The reaction
was stopped by washing the membrane in two baths of deionised distilled water for 2
minutes. The membrane was dried by exposure to air and stored protected from light.
Detailed instructions for the use of the TnT® Quick Coupled
Transcription/Translation System (Promega), the Mini-Protean® II Electrophoresis
Cell (Biorad), the Trans-Blot® Electrophoretic Transfer Cell (Biorad) and the
TM .
Transcend Colorimetric Translation Detection System (Promega) can be found in
their corresponding instruction manuals (see references).
The details of methods specific to each of the genes studied are now described
below.
4.15 Androgen Receptor Gene
Using the published sequence (see references), the following primers were designed
• (c)
(Primer Designer vl. 1 1990 Educational Software) and manufactured by Genosys
Biotechnologies (Europe) Ltd. :
ARG-F 5' -TGCGCGAAGTGATCCAGAACC-3'
ARG-R 5' -CTCATCCAGGACCAGGTAGCC-3'
These generate PCR fragments containing the CAG repeat sequence.
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PCR reactions were performed in 50pl aliquots, each containing 31 pi de-ionised
distilled water, lx PCR reaction buffer (5pl of lOx concentrate used, containing
200mM Tris-HCl pH8-4 and 500mM KC1, Life Technologies'"), 2mM (2pl) MgCb,
5pl Dimethyl Sulfoxide, 200pM (1 pi) deoxynucleoside triphosphates, 20 pmol of
each primer (supplied primers diluted to 20pmol/pl and lpl used), 1 unit of Taq
polymerase (supplied as 5 units/pl, diluted 1:10 and 2pl used, Life Technologies'")
and approximately lOOng (2pl) DNA. The amplification was performed using an
OmniGene thermal cycler (Hybaid, UK) under the following conditions: initial
denaturation at 94°C for 3 minutes; amplification for 38 cycles, with denaturation at
94°C for 45 seconds, annealing at 56°C for 45 seconds and extension at 72°C for 45
seconds; final extension at 72°C for 10 minutes.
The products were denatured and then run on 6% polyacrylamide gels with a 1 Obp
DNA ladder (range 1 Obp - 330bp, Life Technologies'"). The products were then
ranked in order of length. Cycle sequencing of products was unsuccessful. Three
representative products were therefore sent for automated sequencing (DNASHEF,
Dept. ofHaematology, Royal Infirmary of Edinburgh) to confirm the number of
CAG repeats, and these were used as size standards. The products were then re-run,
with those thought to be of equal length adjacent to each other in order to check the
accuracy of the original estimation of length. A second re-run was then performed to
confirm the accuracy of the results. The number ofCAG repeats in each sample
could then be calculated.
The distribution of alleles of the androgen receptor gene, comparing the male breast
cancer patients with 79 male controls, was analysed using the Mann-Whitney test.
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4.16 BRCA1 & BRCA2
The entire coding region and splicing sites of BRCA2 was amplified by polymerase
chain reaction using 62 pairs of primers (designed by Dr. R. Wooster; sequences
provided by Dr. N. Spurr, personal communication). These primers are listed in
Appendix 7-2 and were manufactured by Life Technologies™. A region ofBRCA1
was also amplified (using primers shown in Appendix 7-3) to screen for the
2800delAA mutation that is thought to be a founder mutation in Scotland (Renwick
et al, 1997; Liede et al, 2000). Reactions were performed in 25pl aliquots, each
containing 13-5pl de-ionised distilled water, lx PCR reaction buffer (2-5pl of lOx
concentrate used, containing 200mM Tris-HCl pH8-4 and 500mM KC1, Life
Technologies"), 2mM (lpl) MgCf, 5pl Dimethyl Sulfoxide, 200pM (0-5pl)
deoxynucleoside triphosphates, 10 pmol of each primer (supplied primers diluted to
lOpmol/pl and lpl used), 0.5 units of Taq polymerase (supplied as 5 units/pl, diluted
1:20 and 2pl used. Life Technologies ) and approximately 50ng (lpl) DNA. The
amplification was performed using an OmniGene thermal cycler (Hybaid, UK) under
the following conditions: initial denaturation at 94°C for 3 minutes; amplification for
35 cycles, with denaturation at 94°C for 45 seconds, annealing at 45-60°C
(depending upon the primer used) for 45 seconds and extension at 72°C for 45
seconds; final extension at 72°C for 10 minutes. The annealing temperature for each
pair of primers is shown in Appendix 7-2. Where two temperatures are given then a
touchdown PCR was found to work better, with five amplification cycles at the
higher temperature, followed by 35 cycles at the lower temperature.
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PCR products underwent Heteroduplex analysis and were visualised by staining with
silver nitrate. BRCA2 exons 10, 11 and 27 were also studied by PTT.
PCR products showing variant bands on heteroduplex analysis or PTT were re-
amplified from the genomic DNA and then sequenced. The sequences produced were
compared to the published BRCA2 sequence (details of the exonic and flanking
intronic sequences can be found on the Breast Cancer Information Core).
When mutations and polymorphisms were detected, new primers were designed
(£)
(Primer Designer vl. 1 1990 Educational Software) in order to produce shorter PCR
products covering those areas. This was done in order to maximise the number of
archival samples containing poor quality DNA that could be screened for mutations
already detected in those samples containing better quality DNA. These primers are
listed in Appendix 7-3.
In designing these primers, a number of factors needed to be taken into account. The
computer software used was able to check that the primers designed would not
hybridise to each other and that they should also hybridise to the genomic DNA
under study at similar temperatures. It was also important to design primers that did
not contain long runs of a single nucleotide and whose base composition was 50-60%
GC-rich. It is sufficient for primers to be about 20 nucleotides in length, because the
chances of a perfect match elsewhere in the genome is then extremely low.
Shortening the length of the PCR product produced will mean a greater chance that
the PCR will be successful when the DNA used is of poor quality. However, it has
been shown that the difference in migration between heteroduplexes and
homoduplexes is reduced when the PCR product length is less than 150bp (Ganguly
et al, 2002) which would reduce the sensitivity of heteroduplex analysis. It is also
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important to design primers so that the mutation or polymorphism being screened for
is not too close to one end of the PCR product. If this was the case, then the sequence
change may not alter the conformation of the DNA sufficiently to allow detection by
heteroduplex analysis (Rossetti et al, 1995). It was obviously important to ensure that
heteroduplex analysis could detect sequence changes in PCR products produced
using the new primers. The DNA samples in which mutations had been detected with
the original primers were therefore taken, amplified using the new primers, and used
as positive controls for the heteroduplex analysis.
4.17 CYP17
The primers originally described produce a PCR product of 459bp in length (Carey et
al, 1994). This would clearly restrict the numbers of successful PCR's using DNA
extracted from archival tissue.
The following primers were designed for PCR (Primer Designer v 1.1 1990
Educational Software) and manufactured by Life Technologies™ :
CYP17S-F, 5'-CAAAAGTCAAGGTGAAGATCAG-3'
CYP17S-R, 5'-TAGGGTAAGCAGCAAGAGAG-3'
These generate PCR fragments 150bp in length, including the polymorphic site. PCR
reactions were performed in 50pl aliquots, each containing 3T5pl de-ionised distilled
water, lx PCR reaction buffer (5pl of lOx concentrate used, containing 200mM Tris-
HC1 pH8-4 and 500mM KC1, Life Technologies™), 2mM (2pl) MgCl2, lOOpM
(0-5pl) deoxynucleotide triphosphates, 100 pmol of each primer (supplied primers
diluted to lOOpmol/pl and lpl used), 1 unit of Taq polymerase (supplied as 5
units/pl, diluted 1:10 and 2pl used, Life Technologies "") and approximately lOOng
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(2)0.1) DNA. The amplification was performed using an OmniGene thermal cycler
(Hybaid, UK) under the following conditions : initial denaturation at 94°C for 3
minutes; amplification for 38 cycles, with denaturation at 94°C for 45 seconds,
annealing at 56°C for 45 seconds and extension at 72°C for 45 seconds; final
extension at 72°C for 10 minutes.
1 Op.1 of each PCR product was run on an agarose gel to confirm that the PCR had
been successful. To the remaining 40pl of each PCR product were added 0-2pl
restriction enzyme MspAl (Promega) and 4-5pl 10X Multi-Core™ Buffer (lx =
25mM Tris-Acetate, pH 7.5 at 37°C, lOOmM potassium acetate, lOmM magnesium
acetate, 1 mM DL-Dithiothreitol). The PCR products were digested for 90 minutes at
37°C. The products were separated by electrophoresis on a 4% agarose gel, staining
with ethidium bromide and identified from photographs of the gel under ultraviolet
illumination.
The association between the C allele of the CYP17 gene and breast cancer in the
male and female subjects and controls was analysed using x tests.
4.18 CYP19
Primers as previously described (Polymeropoulos et al, 1991) were manufactured by
Genosys Biotechnologies (Europe) Ltd. and used for PCR :
CYP19-F : 5 '-GCAGGTACTTAGTTAGCTAC-3'
CYP19-R : 5'-TTACAGTGAGCCAAGGTCGT-3'
These generate PCR fragments that include the polymorphic site. PCR reactions
were performed in 50pl aliquots, each containing 36pl de-ionised distilled water, IX
PCR reaction buffer (5pl of lOx concentrate used, containing 200mM Tris-HCl
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pH8-4 and 500mM KC1, Life Technologies'"), 2mM (2pi) MgCb, 200pM (lpl)
deoxynucleoside triphosphates, 40 pmol of each primer (supplied primers diluted to
40pmol/pl and lpl used), 1 unit of Taq polymerase (supplied as 5 units/pl, diluted
TM
1:10 and 2pl used, Life Technologies ) and approximately lOOng (2pl) DNA. The
amplification was performed using an OmniGene thermal cycler (Hybaid, UK) under
the following conditions : initial denaturation at 94°C for 3 minutes; amplification
for 38 cycles, with denaturation at 94°C for 45 seconds, annealing at 53°C for 45
seconds and extension at 72°C for 45 seconds; final extension at 72°C for 10
minutes.
The products were denatured and then run on 6% polyacrylamide gels with a 1 Obp
TM
DNA ladder (range 1 Obp - 330bp, Life Technologies ). The number ofTTTA
repeats in homozygous products were measured by cycle sequencing and these were
used as size standards.
The distribution of alleles of the CYP19 gene, comparing male breast cancer patients
with controls, was analysed using the Mann-Whitney test. Odds ratios with 95%
confidence intervals were calculated to show the risk of developing male breast
cancer associated with each allele.
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4.19 Oestrogen Receptor Gene
The oestrogen receptor gene intron 1 sequence was provided by Dr. Alison Dunning
(personal communication). The following primers were designed (Primer Designer
vl.l @1990 Educational Software) for PCR amplification of the relevant fragment
(128bp) of intron 1 containing the polymorphic site :
ERG1-F : 5 '-CATGTTCTGTGTTGTCCATC-3'
ERG1-R : 5'-GAACCATTAGAGACCAATGC-3'
Primers as previously described (Andersen et al, 1994) were used for PCR
amplification of the relevant fragment of exon 2. Both pairs of primers were
manufactured by Genosys Biotechnologies (Europe) Ltd.
PCR reactions were performed in 50pl aliquots, each containing 36pl (intron 1) or
37pl (exon 2) de-ionised distilled water, IX PCR reaction buffer (5pi of lOx
concentrate used, containing 200mM Tris-HCl pH8-4 and 500mM KC1, Life
TM
Technologies ), 2mM (2pl) MgCh (intron 1) or ImM (lpl) MgC^ (exon 2), 200pM
(2pl) deoxynucleoside triphosphates, 20 pmol of each primer supplied primers
diluted to 20pmol/pl and lpl used), 1 unit of Taq polymerase (supplied as 5 units/pl,
• TM
diluted 1:10 and 2pl used, Life Technologies ) and approximately lOOng (2pl) DNA.
The amplification was performed using an OmniGene thermal cycler (Hybaid, UK)
under the following conditions : initial denaturation at 94°C for 3 minutes;
amplification for 38 cycles, with denaturation at 94°C for 45 seconds, annealing at
54°C (intron 1) or 56°C (exon 2) for 45 seconds and extension at 72°C for 45
seconds; final extension at 72°C for 10 minutes.
The intron 1 products were digested overnight by a restriction enzyme, PvuII (New
England Biolabs®) at 37°C and the exon 2 products by BstUI (New England
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Biolabs®) at 60°C. The products were then separated on 4% agarose gels, stained
with ethidium bromide and visualised under ultraviolet light.
The distributions of alleles of the oestrogen receptor gene, comparing male breast
• 9
cancer patients with controls, were analysed using x tests. Odds ratios with 95%
confidence intervals were calculated to show the risk of developing male breast
cancer associated with each polymorphism.
56
Chapter 5 - Results
Page
5.1 Androgen Receptor Gene 58
5.2 BRCA1 & BRCA2 61
5.3 CYP17 95
5.4 CYP19 97
5.5 Oestrogen Receptor Gene 100
5.6 Cross-Correlation of Results 103
57
5.1 Androgen Receptor Gene
The lengths of the PCR products obtained varied between 224 bp and 272 bp
(corresponding to 14 CAG repeats and 30 CAG repeats respectively). PCR was
unsuccessful with DNA extracted from eight of the archival wax-embedded tissue
sections. An example of the automated sequencing of a CAG repeat sequence is
shown in Figure 51. The distribution of alleles among male breast cancer patients
and controls is shown in Figure 5-2. The median number of CAG repeats in both
groups was 23. There were no statistically significant differences between the two
groups (Mann-Whitney test, p=0916).
Figure 5-1
Automated sequencing of a PCR product containing 25 CAG repeats
gcagt tncagcagcagca gcagca gca gcagca gcagcagnt gcagcagcagcagca gcagca gcagcagcagnagacta
100 110 120 130 140 150 160 170
Three patients showed evidence of two different alleles indicating the presence of
two X chromosomes (Figure 5-3). One of these (MBC17) was recorded on the
Edinburgh Cytogenetics Register with a diagnosis ofKlinefelter's Syndrome. The
other two patients (MBC42 & MBC54) were deceased, but there was no record of
clinical suspicion ofKlinefelter's syndrome in their hospital casenotes. Neither
fathered any children. The data were re-analysed following exclusion of these three
cases. The median number ofCAG repeats for the remaining 53 male breast cancer
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patients was also 23. There were still no statistically significant difference between
cases and controls (p=0-765).
Figure 5*2


























5.2 BRCA1 & BRCA2
52 of the 64 male breast cancer cases were screened successfully for the BRCA1
2800 delAA mutation. None produced variant bands on heteroduplex analysis (HA)
and therefore no BRCA1 2800 delAA mutations were detected.
HA of a number of PCR products generated to screen for this mutation are shown in
Figure 5-4. DNA from a female known to carry the mutation was provided by Dr. B.
Cohen (School of Biomedical Sciences, University of St.Andrews). The PCR product
generated from this DNA sample clearly produced variant bands as shown and was
therefore a useful positive control.
Figure 5*4
Heteroduplex analysis to screen for BRCA1 2800delAA mutation
?C
$C = Female 'control' known to carry BRCA1 2800 delAA mutation
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For the screening of the BRCA2 gene, more than 85% of polymerase chain reactions
were ultimately successful. The DNA derived from certain archival samples was
clearly not of good quality. The results of BRCA2 mutation analysis are shown in
Table 5*1. Germline BRCA2 mutations were identified in 12 of the 64 (19%) male
breast cancer cases. None of these mutations were detected in the control population.
Figure 5-5 demonstrates the detection of a number of these mutations on HA and
Figure 5-6 shows one of the mutations detected on PTT. The sequencing ofDNA
demonstrating each of these mutations are shown in Figures 5-7 - 5T3. These
sequences are read 5'->3' from the bottom of the figure upwards. Exonic sequences
are given in uppercase, intronic sequences in lowercase.
A number of polymorphisms in BRCA2 were also detected. The frequency of these
among male breast cancer cases and controls is shown in Table 5-2.
38/61 (62%) of the male breast cancer patients carry the 203 G—>A exon 2
polymorphism. 52 / 116 of the controls (45%) carry the polymorphism. The
difference between cases and controls is statistically significant (p=0-0272, x2=4-88,
1 d.fi). The odds ratio for the risk of a male with the exon 2 polymorphism
developing breast cancer is calculated as 2-033 (95% confidence interval 1-079 -
3-834). All three male breast cancer cases carrying the 7830 del 16 exon 16 mutation
also carry the exon 2 polymorphism.
Family pedigrees of the 12 males found to carry BRCA2 mutations are shown in
Figures 5-14 to 5-25. Six of these cases (50%) had a history of breast cancer in a
first- or second-degree relative.
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Table 51
Mutations detected in the BRCA2 gene
Mutation Location Putative Coding No. Age at
Effect Cases Diagnosis
1418 insTTAG Exon 10 Frameshift 2 55,71
5910 C—»G Exon 11 Tyr -> STOP 1 66
7165+2 delT Intron 12 Splicing 2 32, 81
7830 dell6 Exon 16 Frameshift 3 73, 75, 79
8560-1 G—>C Intron 18 Splicing 1 39
9522 C-»G Exon 25 Tyr -> STOP 1 62
9877-67 delTTAC Intron 26 Splicing 2 56, 66
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Table 5-2
Polymorphisms detected in the BRCA2 gene among cases and controls
Polymorphism Location Freq. Cases Freq. Controls P 1 d.f.)
203 G-»A Exon 2 38/61 52/116 0-0272
3199 A—>G Exon 11 2/60 8/58 0-0609
4035 T->C Exon 11 12/61 21/80
5972 C—»T Exon 11 7/61 5/34
7470 A—>G Exon 14 11/55 Not done *
8034-14 T—»C Intron 16 5/64 5/43
9485-16 T—»C Intron 24 1/51 2/42
* There was insufficient time at the end of the period of study to determine the
frequency of this polymorphism in controls
Missense sequence variants were found on sequencing 17 of the PCR products that
had produced variant bands on HA. However, none of these were found a second
time after repetition of the PCR's. They were all in DNA extracted from archival
tissue. They were therefore presumed to be due to errors within the PCR process
rather than the HA.
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Figure 5-5
Examples of polymorphisms and mutations detected by heteroduplex analysis




9485-16 T—»C Polymorphism (Intron 24)
9522 C—»G Mutation (Exon 25)
I
P WT





P = Polymorphism M = Mutation WT = Wild-type
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Figure 5-6
A truncating mutation in exon 11 of BRCA2 demonstrated by protein truncation test
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Figure 5 7
Cycle sequencing of PCR product containing BRCA2 1418 insTTAG mutation







Cycle sequencing of PCR product containing BRCA2 5910 C->G mutation










Cycle sequencing ofPCR product containing BRCA2 7830 dell6 mutation





Cycle sequencing of PCR product containing BRCA2 8560-1 G->T mutation





Cycle sequencing of PCR product containing BRCA2 9522 C—>G mutation





Cycle sequencing ofPCR product containing BRCA2 9877-67 delTTAC mutation



















































































































































































































































































































































































































































Pedigrees for four of the males in whom no BRCA2 mutations were detected are
shown in Figures 5-26 to 5-29. MBC30 developed breast cancer at the age of 30. His
mother had breast cancer aged 57 and his maternal grandmother had ovarian cancer
aged 58. MBC33 had a niece who developed ovarian cancer aged 58, another niece
with breast cancer aged 58 and her daughter developed breast cancer aged 28.
MBC46 had a daughter who developed breast cancer aged 36. MBC77 had breast,
gastric and prostate cancer. His sister had breast cancer aged 50 and his father
developed oral cancer aged 47.
Referring to the family pedigrees shown in Figures 5-14 to 5-25, the 12 male
probands found to carry BRCA2 mutations had 35 female first-degree relatives in
total. Of these, 9 (26%) had a history of breast cancer. Examination of the pedigrees
for the 52 male probands in whom no BRCA2 mutations were detected, showed a
total of 133 female first-degree relatives. Of these, 5 (4%) had a history of breast
cancer.
Figure 5-30 shows the estimated cumulative risks of breast cancer in female first-
degree relatives of proven BRCA2 mutation carriers (indicated in red) and the
relatives of those males not found to carry mutations (shown in blue). The curves
were plotted using the Kaplan-Meier method (Bland & Altman, 1998).
The estimated cumulative risk of breast cancer is significantly higher in the group of
first-degree female relatives of proven BRCA2 mutation carriers, compared to
relatives of those males in whom no mutation was detected (p=0-00002, log-rank
test). For first-degree female relatives of male breast cancer cases in whom a BRCA2
mutation has been detected, the estimated cumulative risk of breast cancer to age 73
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is 34-8% (95% confidence interval 28-1% - 43-1%). However, if no BRCA2 mutation
is detected in the male proband, then estimated cumulative risk of breast cancer in
first-degree female relatives by age 72 is 7-8% (95% confidence interval 7-3% -
8-4%). This is similar to the risk of female breast cancer in the Scottish population as
a whole, which is reported to be 7-9% to the age of 74 (Cancer Registration Statistics
Scotland 1986- 1995).
Figure 5-30
Estimated cumulative risks of breast cancer in female first-degree relatives of male
breast cancer cases
— Relatives of Mutation Carriers






















Penetrance (the probability of cancer in a mutation carrier) can be estimated by
calculating twice the age-specific cancer incidence in first-degree relatives of
mutation carriers, minus the incidence in first-degree relatives of non-carriers
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(Thorlacius et al, 1998). In our study the estimate of breast cancer penetrance for the
BRCA2 mutations detected as a whole, in females by age 72-73, is therefore 61-7%
(95% confidence interval 48-8% - 77-8%).
The numbers of other cases of different cancers among male and female first-degree
relatives of the male probands are shown in Table 5-3. The numbers of these other










Ovary 0/35 * 0/133 *
Male First-degree
Relatives









* Note, there were no cases of ovarian carcinoma among first-degree relatives,
however there were a number of cases among second-degree relatives.
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The clinical data are summarised in Table 5-4. The mean age at diagnosis of the
group of 12 male breast cancer patients found to carry germline BRCA2 mutations
was not significantly different from that for the group of 52 without mutations. There
were also no significant differences between the two groups in terms of the
histological classification of tumours, disease stage at presentation or risk of loco-
regional relapse within 5 years.
Table 5-4
Clinical data for the male breast cancer cases
BRCA2 -ve BRCA2 +ve P
Mean Age (Range) 65.4 (26-85) 63.3 (32-81) 0.676 (t test)
Histology
No special type 39 9 0.802 (x2 test)
Special type 6 1
None 5 2
Not known 2 0
Stage at
presentation




Not known 3 0




Kaplan-Meier estimates of the cumulative survival for both groups are shown in
Figure 5-31. Although the curves appear to diverge after four years, there was no
statistically significant difference between the two groups (p=0-449, log rank test).
Figure 5-31






The different alleles of the CYP17 gene as demonstrated by agarose gel
electrophoresis are shown in Figure 5-32. The results showing the genotyping of the
cases and controls are shown in Table 5-5. The results show that a C allele is found
significantly more frequently in male breast cancer patients than in male controls
(X2=4.308, 1 d.f., p=0.038). The odds ratio for the risk of a male with a C allele
developing breast cancer is calculated as 2.10 (95% confidence interval 1.04-4.27).
There were no significant differences between female breast cancer patients and
female controls (x =1.895, 1 d.f., p=0.169; odds ratio=0.56, 95% confidence interval
0.25-1.28). The distribution of alleles in both control groups is in Hardy-Weinberg
equilibrium (Table 5-6).
Figure 5*32
Different alleles of the CYP17 gene demonstrated by agarose gel electrophoresis
TT TT TC TC CC CC
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Table 5-5
CYP17 Genotype Frequencies Among Breast Cancer Patients and Controls
Males Females
Genotype Cases (n=64) Controls (n=81) Cases (n=39) Controls (n=58)
TT 17(26.6%) 35 (43.2%) 21 (53.8%) 23 (39.7%)
TC 42 (65.6%) 39 (48.1%) 13 (33.3%) 28 (48.3%)
CC 5 (7.8%) 7 (8.6%) 5 (12.8%) 7(12.1%)
TC/CC 47 (73.4%) 46 (56.8%) 18(46.2%) 35 (60.3%)
Table 5-6
CYP17 Genotype Frequencies In Controls and Expected Frequencies Under Hardy-
Weinberg Equilibrium
Male Controls Female Controls
Observed Expected Observed Expected
TT 35 36.7 23 23.6
TC 39 35.7 28 26.8
CC 7 8.67 7 7.60
(X2=0.705, 2 d.f., p=0.703) (^=0.116, 2 d.f., p=0.943)
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5.4 CYP19
PCR was unsuccessful with 10 of the DNA samples derived from archival wax-
embedded tissue sections, giving a total of 54 case samples (108 alleles) analysed.
Seven different alleles of the CYP19 gene were detected (Figure 5-33).
Figure 5*33
Examples of the seven different alleles of the CYP19 gene found in male breast
cancer patients and controls.
lObp DNA
SHHB
No. TTTA Repeats 7 (-3) 8 10 11 12 13 13
7 (-3) 7 7 11 7 7 (-3) 11
MBC8F MBC8
The allele distribution of the CYP19 gene in male breast cancer patients and controls
is shown in Table 5-7. There were no significant differences in the distribution of
alleles between cases and controls (p=0.838). We have found two different alleles
containing 7 TTTA repeats (corresponding to PCR products of 168bp and 171 bp in
97
length). Cycle sequencing of these alleles revealed that the shorter allele, designated
(TTTA)7-3, had a 3-bp (CTT) deletion 50bp upstream from the 5' end of the TTTA
repeat sequence (Figure 5-34). One of the male breast cancer patients (MBC8) had an
allele containing 13 repeats. A blood sample was obtained from his father (MBC8F),
who had not had breast cancer. Analysis ofDNA extracted from this showed the
same (TTTA)i3 allele.
Table 5-7







Odds Ratio & 95%
C.I.
(TTTA) (7.3) 168 35 (32.4%) 48 (30.4%) 1.10(0.649 - 1.86)
(TTTA) 7 171 20(18.5%) 30(19.0%) 0.970 (0.518 - 1.82)
(TTTA) 8 175 11 (10.2%) 16(10.1%) 1.01 (0.448 -2.26)
(TTTA)io 183 1 (0.93%) 2(1.3%) 0.729 (0.0653 - 8.14)
(TTTA) n 187 36 (33.3%) 57(36.1%) 0.886 (0.529- 1.48)
(TTTA) 12 191 4 (3.7%) 5 (3.2%) 1.18 (0.309 -4.49)




Sequencing of part of the (TTTA) n and (TTTA) (7.3) alleles of the CYP19 gene.





5'- TTAGTTAGCTACAATCTTCTTTTTTGTCTATGAATGTGC - 3'
99
5.5 Oestrogen Receptor Gene
PCR was unsuccessful with the DNA from one case (intron 1 and exon 2) and one
control (intron 1 only). Different alleles of intron 1 and exon 2 demonstrated by
agarose gel electrophoresis are shown in figures 5-35 and 5-36 respectively. The
distribution of intron 1 alleles is shown in Table 5-8 and the distribution of exon 2
alleles in Table 5-9.
Figure 5*35









The distribution of alleles of oestrogen receptor gene intron 1





Taking TC and CC together, x,2=0.54 (1 df), p=0.464
The odds ratio for the risk of breast cancer in a male with a polymorphic allele in
intron 1 is 1-34 (95% C.I. 0-614 to 2-91).
101
Table 5-9
The distribution of alleles of oestrogen receptor gene exon 2





17 / 63 (27%) of males with breast cancer carry the polymorphic allele in exon 2
compared to 10/77 (13%) of controls. This difference was statistically significant
(X2=4-361, 1 d.f., p=0-0368). The odds ratio for the risk of breast cancer in a male
with a polymorphic allele in exon 2 is 2-476 (95% C.I. 1 -041 to 5-890).
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5.5 Cross-Correlation of Results
A table of the results for all of the male breast cancer cases is shown in Appendix
7-4. This shows the different alleles detected in each of the genes under study.
It is possible to cross-correlate these results in order to see if there are any
combinations of alleles of different genes that could be regarded as conferring an
increased risk.
The expected frequency of a combination of two of the polymorphisms can be
calculated simply by multiplying the observed frequencies of each of the individual
polymorphisms together. This can then be compared to the observed frequency of the
combination of polymorphisms.
For example, 17/63 cases carry the oestrogen receptor gene exon 2 polymorphism.
38/61 cases carry the BRCA2 exon 2 polymorphism. Both alleles were successfully
genotyped in 60 cases. The expected frequency of carriage of both polymorphisms
would be 17/63 x 38/61 =0.1681 or 10/60 cases. The observed frequency is 9/60
cases, which is marginally lower than the expected frequency. The carriage of
polymorphisms in oestrogen receptor gene exon 2 together with BRCA2 exon 2
therefore does not appear to be a 'high-risk' combination.
There are many more different alleles of the androgen receptor gene and CYP19
gene, therefore this type of analysis for these genes in combination with the other
genes as above is more difficult. For this reason, the alleles of exon 1 of the androgen
receptor gene containing between 27 and 30 repeats are taken together, and studied
in combination with the other genes. In our study, none of the alleles of the CYP19
emerged as a 'high risk' allele. One previous study concluded that the (TTTA) 7
allele was associated with increased risk of female breast cancer (Siegelmann-
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Danieli and Buetow, 1999). Another study found the (TTTA) 12 allele significantly
more frequently in female breast cancer patients than in controls (Kristensen et al,
1998). For this reason, only these two alleles of the CYP19 gene have been included
in the cross-correlation of our results.
The cross-correlation of results, showing the observed (Obs) and expected (Exp)
frequencies of combinations of alleles is in Table 5-10.
There are clearly no significant differences between the observed and expected
frequencies of any of the combinations of alleles studied.
The expected number of cases carrying a BRCA2 mutation and the (TTTA) 7 allele
ofCYP19 would be three. The observed number was five. Interestingly, two of the
five cases were aged only 32 and 39 at diagnosis, and another two of the cases had
two and three affected first-degree female relatives respectively.
Five cases were found to have an androgen receptor gene exon 1 containing between
27 and 30 CAG repeats together with a BRCA2 exon2 polymorphism. The expected
frequency of this combination would be 3/53 cases. It is therefore possible that
carriage of the BRCA2 exon 2 polymorphism, in combination with an androgen
receptor gene exon 1 containing greater than 27 CAG repeats confers a particularly
increased susceptibility to male breast cancer. However the numbers are too small to
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6.1 Androgen Receptor Gene
In this part of the study looking at the androgen receptor gene, we did not observe
any overall difference between the median CAG repeat length comparing male breast
cancer patients with controls. However, no males in the control group had alleles
containing more than 28 CAG repeats, whereas two of the male breast cancer
patients had alleles with 29 and 30 repeats respectively. Only one of the male breast
cancer patients had an allele containing 18 repeats or less, compared with six of the
controls.
To our knowledge, the length of this CAG repeat has been studied in only one group
ofmale breast cancer patients previously (Haraldsson et al, 1998). There was found
to be no significant difference between male breast cancer cases and controls.
However, sequences of 30 repeats or more were found only among cases. Our results
are consistent with these findings. In addition, it has been observed that women who
are carriers of BRCA1 mutations are at a significantly increased risk of breast cancer
if they carry at least one androgen receptor gene allele with 28 or more CAG repeats
(Rebbeck et al, 1999). We believe that a relatively long CAG repeat sequence within
the androgen receptor gene may be implicated in a few cases ofmale breast cancer.
Conversely, a short CAG repeat sequence might offer a degree of protection against
male breast cancer.
It is well recognised that Klinefelter's syndrome is associated with an increased risk
ofmale breast cancer (Jackson et al, 1965). One of the male breast cancer patients in
our study was known to have had Klinefelter's syndrome. Our study of the androgen





Thirteen previous publications record the frequency ofBRCA2 mutations in male
breast cancer populations. Four of these were small series (less than 20 cases).
Csokay et al (1999) detected mutations in six out of 18 cases. None had a family
history of breast cancer. Diez et al (2000) found mutations in three out of 17 cases.
However six of the 'cases' were affected females who had an affected first-degree
male relative. Wolpert et al (2000) described mutations in two out of a very small
series of 14 cases (unselected for family history). Pages et al (2001) reported an even
smaller series of 12 affected males who were all from families with at least two cases
of female breast cancer. Three truncating mutations and one missense variant were
detected. However the missense variant was found in a family containing two cases
ofmale breast cancer.
Four of the series reported larger numbers of cases, but detected relatively few
mutations. Friedman et al (1997) found mutations in only two out of 54 cases
studied. Mavraki et al (1997) detected mutations in 3 out of 28 cases. However two
of the 28 'cases' were affected female relatives of male cases and one of the
'mutations' was a missense variant of unknown significance. Kwiatkowska et al
(2001) reported mutations in four out of 37 cases. There were another three cases
with missense variants. Ottini et al (2003) reported a series of 25 male breast cancer
cases recruited regardless of family history, three ofwhom were found to carry
mutations.
Three moderate-sized series have detected larger numbers ofmutations. Couch et al
(1996) identified mutations in seven out of 50 cases. The authors stated that the
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males were not selected on the basis of family history, however six of the seven
cases found to carry mutations had a family history of breast cancer. The highest
frequency of BRCA2 mutations reported to date has been in a series ofmale breast
cancer cases from Iceland. Thorlacius et al (1998) found a single founder mutation in
13 out of 34 cases. Another series in which a high frequency ofBRCA2 mutations
was detected was from Sweden. Haraldsson et al (1998) reported mutations in seven
out of 34 cases. Of note was the fact that only one of these cases had a family history
of breast cancer.
The largest published series reported 124 male breast cancer cases from Israel
(Struewing et al, 1999). A common Ashkenazi Jewish founder mutation (6174 delT)
was detected in 15 of the cases. However, the study was limited in that only this
single mutation was screened for.
Basham et al (2002) published a large study of 94 cases from England. Only five
cases were found to carry truncating mutations and only one of these five reported a
history of breast cancer in a first-degree relative.
A representation of all BRCA2 mutations found to date in Scotland and Northern
Ireland is shown in Figure 6.1. The numbers ofmutations found in male breast
cancer cases and their location within the BRCA2 gene are highlighted. It can be
seen that the distribution ofmutations found in males is different from females. Only
one of the mutations found in male cases is within the so-called ovarian cancer
cluster region (OCCR) that was proposed by Gayther et al (1997). This is consistent
with the low number of ovarian cancers found among relatives of the male BRCA2






































































































































The BRCA2 mutations that we have identified are discussed in more detail below.
Frameshift Mutations
The 1418 insTTAG exon 10 mutation has previously been reported in a Scottish
family containing five cases of female breast cancer (Gayther et al, 1997). This
mutation within codon 473 results in a frameshift, which is predicted to produce
premature termination of translation at codon 497. However, using PTT, we were not
able to demonstrate a truncated protein product. The reason for this is unknown.
The 7830 del 16 exon 16 mutation has been reported previously in a Japanese family
with four cases of female breast cancer (Katagiri et al, 1998). This mutation also
results in a frameshift. The amino acid sequence would be altered such that a
termination codon is not produced until further downstream than normal. Exon 16
normally codes for a sequence of 68 amino acids. This mutation is predicted to result
in the translation of an abnormal sequence of 90 amino acids. Due to the relatively
small size of exon 16 and the close proximity of the mutation the intron / exon
border, the methods used in our study for PTT were not suitable to confirm the
translation of a truncated protein.
Nonsense Mutations
The 5910 C—»G mutation has been reported recently (Risch et al, 2001). We have
demonstrated that this mutation in exon 11 results in a truncated protein (Figure 5-6).
This is easily explained as the mutation is predicted to change codon 1970 to a
termination codon.
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The 9522 C—>G mutation in exon 25 has been recorded on the Breast Cancer
Information Core database. This mutation results in codon 3174 becoming a
termination codon and is therefore predicted to result in a truncated protein. Due to
the relatively small size of exon 25, the methods used in our study for PTT were not
suitable to confirm the translation of a truncated protein.
Splicing Mutations
The process ofRNA transcription involves a splicing process whereby the intronic
RNA segments are removed, and the exonic RNA segments are joined end-to-end.
This process depends upon the identification of certain DNA sequences that are
present at the so-called splice junctions (the boundaries between introns and exons).
The DNA sequences that are present at the exon/intron and intron/exon boundaries
(otherwise known as splice junctions) are shown in Figure 6-2. The nucleotides
highlighted in bold are invariant and are vitally important for normal splicing to
occur. There is evidence from other genes (e.g. p53) that base changes within a short
distance of these splice junctions may also affect the splicing process (Varley et al,
2001).
The branch site is another sequence within the intron that is also important for
splicing. This is also shown in Figure 6-2 and it is usually located anywhere from 6
to 59 nucleotides upstream of the splice acceptor site (Maquat, 1996).
The RNA splicing mechanism involving the branch site is illustrated in Figure 6-3.
The exonic RNA segments are spliced together and the intronic RNA is released in























































The mechanism ofRNA splicing
Cleavage at 5' end
Exon GIJ
Branch Site
— A " AG Exon
Lariat Formation
Exon GU1 AG Exon
Exon c UGA
Cleavage at 3' end
Exon
Exon Exon o+ A AG
Modified from Figure 1-16, pi8 (Strachan & Read, 1997)
114
The BRCA2 mutations found in our study that are thought to affect splicing are now
discussed below.
The 7165+2 delT mutation has not been previously recorded. It will alter the
sequence of the splice donor site at the 5' end of intron 12.
5'-CCAGATGgttaaaatt-3' Wild-type
5'-CCAGATGgtaaaatt-3' Mutant
Whilst the invariant GT within the splice donor site is unaffected, the third base is
changed T—»A. The effect of this is unknown. A mutation within the splice donor
site of BRCA2 intron 7 (859+2 T—»G) has been shown to result in the deletion of
exon 7 (Pyne et al, 2000). It is possible that the intron 12 mutation detected in our
study might have a similar effect.
The 8560-1 G—»T mutation has not previously been recorded. It will alter the
sequence of the splice acceptor site at the 3' end of intron 18.
5'-aatttgtccagATTTCTGCTAACAGTACTC-3' Wild-type
5'-aatttgtccatATTTCTGCTAACAGTACTC-3' Mutant
The invariant AG is altered and it is therefore highly likely that splicing will be
affected.
The 9877-67 delTTAC variant in intron 26 has been reported in two unrelated cases
with ovarian carcinoma (Takahashi et al, 1996). The authors suggested that this
deletion may affect splicing, but did not explain how.
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Taking the consensus sequence of the intronic branch site (Figure 6-2), the closest
point to the intron/exon border where this sequence is found in BRCA2 intron 26 is
shown in Figure 6-4.
Figure 6*4
The sequence of the 3'-end of BRCA2 intron 26
Intron 26 Exon 27
agtta ctttgat ttagttttttatgttactacataattatgataggctacgttttcatttttttatcag ATGT
Branch Site
It can be seen that deletion of the TTAC, as shown in red, would result in a C—»G
change in the first base of the branch site sequence. In vitro studies have shown that
mutation of the invariant adenine within the branch site has the most significant
effect upon splicing, but change in the first base from C^T results in a smaller effect
(Reed & Maniatis, 1988). However, the effect of a C—»G change in the first base of
the branch site sequence is not known. An effect on splicing is likely to be important,
though, because there is recent evidence suggesting that exon 27 is involved in the
interaction between BRCA2 and RAD51 (Donoho et al, 2003). If this variant does
have an effect on splicing then it may alter the level of expression of the BRCA2
gene, or it may result in an abnormal protein equivalent to a deletion of exon 27.
Neither of these possible effects would result in an abnormal protein that would be
visible on PTT of exon 27. This is in agreement with our results.
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We have identified germline BRCA2 mutations in 19% of male breast cancer cases
studied from the South East Scotland region. This is a higher frequency than
previously reported from the U.K. (Mavraki et al, 1997; Basham et al, 2002) or the
U.S.A. (Couch et al, 1996; Friedman et al, 1997). It is possible that germline BRCA2
mutations may account for a higher proportion of male breast cancer cases than
previously thought. Previous studies may have missed potentially important
mutations within splicing regions or may have classified such mutations as
unimportant. A number of previous studies have shown that BRCA2 mutations in
male breast cancer are not necessarily associated with a positive family history of
breast cancer, the proportion of cases carrying BRCA2 mutations that have a positive
family history ranges from 0% to 86% (Csokay et al, 1999; Couch et al, 1996). Our
study is in agreement with this, although positive family history was recorded for six
of our twelve cases. Analysis of the family pedigrees identifies four further males in
whom no BRCA2 mutation was detected, but whose family history is suggestive of
there being a genetic abnormality within the family. It is possible that our screening
of the BRCA2 gene has missed a number of mutations (see below). Alternatively,
these males may carry a mutation in another gene, for example BRCA1.
Previous studies have found the frequency of the 203 G->A exon 2 polymorphism to
be between 17% and 22% in control populations (Couch et al, 1996; Friedman et al,
1997). These studies did not find a significantly higher frequency of the
polymorphism among male breast cancer patients. It would appear that this
polymorphism is commoner in the S.E. Scotland population as a whole (45% in our
study). We have also shown that a significantly higher proportion of the male breast
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cancer cases in our study (62%) carry the polymorphism. There are several possible
reasons for this. This polymorphism may be in linkage disequilibrium with the exon
16 mutation, which is the commonest mutation found in this male breast cancer
population. It is also possible that this polymorphism may in some way alter the
expression of the BRCA2 gene, as has been suggested (Mariani-Costantini et al,
personal communication).
A small number of samples studied (four cases and five controls) were found to be
homozygous for the BRCA2 exon 2 polymorphism. These were detected on
heteroduplex analysis as a bandshift (Figure 6-5). One can only speculate on how a
single base change present on both alleles might alter the conformation of the DNA
sufficiently to slow its migration through the non-denaturing gel.
Figure 6-5





N:N = Homozygous wild-type N:P = Heterozygous for polymorphism
P:P = Homozygous for polymorphism
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Another curious finding is that some of the sequencing films show apparent
homozygosity for mutations (Figures 5-9 and 5-10). This could be explained if the
majority of the DNA in that particular sample was derived from tumour tissue, and
the wild-type allele has been 'knocked out'. However, all three of the cases carrying
the 7830 dell6 exon 16 mutation (Figure 5T0) were heterozygous for the 203 G->A
exon 2 polymorphism, therefore the DNA from each of these samples must contain
two alleles ofBRCA2 exon 2. It is therefore possible that only part of the wild-type
BRCA2 allele has been 'knocked out'. Another possibility may be that the wild-type
allele has not been amplified during PCR, perhaps due to the presence of a
polymorphism that inhibits primer annealing.
All of the other polymorphisms identified in our study have also been described
previously (Tavtigian et al, 1996; Takahashi et al, 1996; Friedman et al, 1997; Breast
Cancer Information Core).
All variant bands found on HA correlated with visible sequence variants on
subsequent cycle sequencing. We can therefore assume that the specificity ofHA and
the sensitivity of sequencing in our study were both 100%. According to published
series, the sensitivity ofHA appears to be between 60% and 100%. To evaluate the
sensitivity ofHA in this study would have required sequencing all PCR products,
which clearly was not practical. As already indicated, for the screening of BRCA2,
approximately 85% of PCR's were ultimately successful. Assuming a sensitivity for
HA of 80%, then we can estimate that in this study the sensitivity for the screening
process ofBRCA2 as a whole was 0 85 x 0 80, or 68%. It is therefore possible that
we have missed almost one third of the BRCA2 mutations present in these cases.
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A review of studies reporting survival in female breast cancer occurring in
association with BRCA2 mutations, stated that no conclusion could be drawn as to
whether carriage of a BRCA2 mutation was associated with a worse or better
prognosis (Verhoog et al, 2000). However, there are no previously published data on
outcome in male breast cancer associated with BRCA2 mutations. Our data indicate
that carriage of a germline BRCA2 mutation in a male who has developed breast
cancer has no significant effect on age at diagnosis, histological classification of the
tumour, disease stage at presentation or risk of loco-regional relapse within 5 years,
or survival.
Other studies have reported associations between BRCA2 mutations and a variety of
other cancers. However, in our study, within the group of families in whom BRCA2
mutations have been detected, there do not appear to be an excess of other cancers,
although our analysis has largely been confined to first-degree relatives.
Use of the Scottish public records by an experienced genealogist has provided us
with detailed and complete family pedigrees in the majority of cases. Information
provided by the Cancer Registry has also given us accurate data on cases of cancer
among relatives of the male probands. The age of onset of cancer is known for the
majority of affected relatives, rather than simply the age at which the individual died.
This allows a more accurate estimate of risk.
We have shown that the risk of developing breast cancer among female first-degree
relatives ofmale breast cancer probands is significantly increased if the male is a
carrier of a BRCA2 mutation. However, if the male does not carry a BRCA2
mutation, then the risk of developing breast cancer in his first-degree female relatives
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is no greater than that of the general population. This suggests that BRCA2
mutations account for the majority of cases of familial breast cancer, when there is an
affected male within the family. It would also appear that intensive screening of
female relatives of male breast cancer cases is only necessary if a BRCA2 mutation
is found in the male proband.
Previous population-based studies have estimated the breast cancer penetrance, by
age 70, for BRCA2 mutations to be 26% (Satagopan et al, 2001), 28% (Warner et al,
1999), 37% (Thorlacius et al, 1998) and 56% (Anglian Breast Cancer Study Group,
2000). For BRCA1/2 mutations combined, penetrance by age 70 has been estimated
to be between 40% (Hopper et al, 1999) and 56% (Struewing et al, 1997). Other
studies have given higher estimates for BRCA2 mutations of 79-5% (Easton et al,
1997) and 84% (Ford et al, 1998). However, these studies were in 'high-risk' breast
cancer families, each containing multiple cases of female breast cancer.
We have estimated that the breast cancer penetrance for the BRCA2 mutations, as a
whole, in our study to be about 62% for females by the age of 72-73. The male breast
cancer cases in our study were not selected on the basis of family history. The
potential for ascertainment bias is therefore eliminated. However, the estimate of
62% in our study is higher than the estimates of penetrance given in the previously
published population-based series shown above. It is possible that BRCA2 mutations
associated with male breast cancer carry a higher risk for females (i.e. these
mutations have a higher penetrance). Alternatively, families that contain affected
males may also carry other genetic variants that either increase breast cancer risk
themselves or modify the penetrance of BRCA2 mutations in females. It is known
from the studies of the Icelandic founder BRCA2 mutation, that the penetrance of a
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single BRCA2 mutation can vary between different families (Thorlacius et al, 1997).
This provides further evidence for the existence of other factors that modify the
effects of BRCA2 mutations.
One way of attempting to identify these factors is by looking again at BRCA2
function. It has been shown that chromosomal instability in cells without functional
BRCA2 normally results in death of these cells due to checkpoint mechanisms and
apoptosis (Patel et al, 1998). Inactivation of BRCA2 alone therefore cannot be
sufficient to result in carcinogenesis. It is possible that secondary mutations occur
that either inactivate the cell-cycle checkpoints or prevent apoptosis. Cells containing
damaged DNA could then remain viable and have the opportunity to become tumour
cells.
The p53 gene mediates cell-cycle arrest and apoptosis after DNA damage has
occurred (Levine, 1997). There is evidence that p53 interacts functionally with
BRCA2 and RAD51 in vivo (Marmorstein et al, 1998). It has been shown in a murine
model that loss of functional BRCA2 together with p53 frequently leads to the
development of breast tumours (Jonkers et al, 2001). Another study has suggested
that the loss ofBRCA2 alone allows chromosomal abnormalities to accumulate in
cells until eventually, p53-mediated apoptosis occurs. When BRCA2 and p53 are
both lost, then DNA damage cannot result in either cell-cycle arrest or apoptosis
(Cheung et al, 2002). Mutations in the p53 and Bubl genes inactivate cell-cycle
checkpoints, resulting in transformation of cells homozygous for truncated BRCA2
into tumour cells (Lee et al, 1999). Amplifications of the AURORA-A gene and
associated increased protein expression occur in 12% - 62% of epithelial carcinomas.
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This has been suggested as an alternative mechanism for disruption of the normal
cell-cycle checkpoint (Anand et al, 2003).
Knowledge of the process of homologous DNA repair is now extending beyond the
interaction between BRCA2 and RAD51. Fanconi anaemia is an autosomal recessive
disorder associated with an increased risk of cancer. Interactions between Fanconi
anaemia proteins and BRCA2 have been demonstrated, although how these proteins
contribute to DNA repair is not fully understood (Hussain et al, 2003). The protein
kinases ATM (which is mutated in ataxia-telangectasia) and CHEK2 are also
involved in the mechanism by which cells are able to recognise double-strand DNA
breaks (Venkitaraman, 2003). Exactly how they interact with the other components
of the DNA repair pathway is not yet known.
Further understanding of the mechanisms by which BRCA2 is involved in DNA
repair, in particular its interaction with the other genes mentioned above, will
inevitably lead to better identification of individuals at increased risk of breast
cancer. It may also provide new opportunities for cancer treatment.
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6.3 CYP17
This is the first study that attempts to evaluate the possible role of a polymorphism of
the CYP17 gene in the development ofmale breast cancer.
We have found that the polymorphic T—»C substitution within the CYP17 gene
occurs significantly more frequently in male breast cancer patients than in male
controls. These results are consistent with other reports that there may be a hormonal
contribution to the development of male breast cancer (Jackson et al 1965, Lobaccaro
et al 1993, Wooster et al 1992).
We have also studied a small group of female breast cancer patients from the same
geographical region. We found no association between the presence of a C allele of
the CYP17 gene and female breast cancer. The first study that looked at this
polymorphism in female breast cancer patients (Feigelson et al 1997), found a
significant association only after sub-selecting those patients that presented with
advanced disease. The second, and much larger, study (Dunning et al 1998) did find
a small increase in the risk of breast cancer associated with the C allele, but this
increase was not statistically significant. It is possible that the T—»C polymorphism
in the CYP17 gene is associated with higher levels of serum oestrogens, but because
the endogenous oestrogen level is higher in females than in males, a further increase
does not have a significant effect. The association between an increase in the levels
of serum oestrogens and the development of breast cancer may therefore be
detectable only in males, or perhaps as previously suggested (Dunning et al 1998), in
post-menopausal females.
Several recently published studies looking at the CYP17 polymorphism in prostate
cancer, have produced contradictory results. One study found the reverse of the
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association that we detected in male breast cancer. Men homozygous for the T (wild-
type) allele had a significantly higher risk of prostate cancer than those homozygous
for the C (polymorphic) allele (Habuchi et al, 2000). However, another study found
an increased risk of prostate cancer in men homozygous for the polymorphic allele
(Gsur et al, 2000).
Further studies of this type are required, specifically to test for any association
between the polymorphism of the CYP17 gene and levels of serum oestrogens in
males.
6.4 CYP19
This is the first study that attempts to determine whether the length of the
tetranucleotide repeat sequence within intron 5 of the CYP19 gene influences the
development of male breast cancer. Two recent studies have determined the
distribution of alleles among female breast cancer patients and controls. The first of
these studies (Kristensen et al, 1998) found five different alleles containing 7,8,9,11
and 12 repeats. The allele containing 12 repeats was found significantly more
frequently in female breast cancer patients than in controls. The second of the studies
(Siegelmann-Danieli and Buetow, 1999) described eight different alleles by PCR
product length. Details of the numbers of tetranucleotide repeats were not given.
Alleles of 168bp and 171 bp in length were found, presumably corresponding to the
two different alleles containing 7 repeats found in our study, although the 3-bp
deletion was not characterised. However, this deletion has been described previously
in a Japanese study (Kurosaki et al, 1997). From their study, Siegelmann-Danieli and
Buetow (1999) conclude that the 171bp allele represents a high-risk allele, whereas
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the 187bp and 191 bp alleles (corresponding to 11 and 12 repeats respectively, from
our data) are considered to confer low risk. These conclusions are contradictory to
those drawn by Kristensen et al (1998).
Contrary to published (and mutually incompatible) findings in female breast cancer,
our study found no significant differences in distribution of alleles between male
breast cancer cases and controls.
Patient MBC8, who has an allele with 13 repeats, was diagnosed with breast cancer
at a very young age (26 years), but has no family history of cancer. This allele was
inherited from his father and therefore does not represent a de-novo mutation. It
certainly represents a rare variant within the South East Scotland population, but is
most likely to be an incidental finding.
6.5 Oestrogen Receptor Gene
In this study we examined the frequencies of two oestrogen receptor gene
polymorphisms in a group ofmale breast cancer patients from the South East of
Scotland. We have demonstrated an association between a polymorphism in exon 2
of the oestrogen receptor gene and male breast cancer. There was no such association
with a polymorphism in intron 1. It is possible that the exon 2 polymorphism has an
effect on the level of transcription of the gene, and this would be an interesting area
for further study. A possibility for further study would be to perform
immunohistochemistry to measure the oestrogen receptor status of the primary
tumours. It would then be possible to determine whether there are any associations
between polymorphisms in the oestrogen receptor gene and oestrogen receptor
expression.
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This is the second modifying polymorphism that we have associated with an
increased risk ofmale breast cancer. We believe that this further illustrates the
potential importance of these low-penetrance genes in the development of breast
cancer. Larger studies are required to determine whether the associations between the
modifying polymorphisms and male breast cancer are strengthened by the addition of
more male breast cancer cases.
6.6 Cross-Correlation Of Results
The expected number of cases carrying a BRCA2 mutation and the (TTTA) 7 allele
of CYP19 would be three. The observed number was five. Interestingly, two of the
five cases were aged only 32 and 39 at diagnosis, and another two of the cases had
two and three affected first-degree female relatives respectively. The numbers of
cases are very small, but it is possible that the presence of this allele ofCYP19 has a
modifying effect upon the penetrance of some of the BRCA2 mutations found in our
study.
Five cases were found to have an androgen receptor gene exon 1 containing between
27 and 30 CAG repeats together with a BRCA2 exon2 polymorphism. The expected
frequency of this combination would be 3/53 cases. It is therefore possible that
carriage of the BRCA2 exon 2 polymorphism, in combination with an allele of exon
1 of the androgen receptor gene containing greater than 27 CAG repeats, confers a
particularly increased susceptibility to male breast cancer. However the numbers are
again too small to allow any meaningful statistical analyses.
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6.7 Conclusions
Our study of 64 male breast cancer cases from the South East of Scotland is one of
the largest and most comprehensive reported to date. We performed comprehensive
screening of the BRCA2 gene and detected mutations in 19% of cases. This is an
appreciably higher proportion than previously recorded for U.K. populations. The
explanation for this may lie in genetic differences between the Scottish and other
U.K. sub-populations and/or in our recognition of pathogenic splice-site mutations
previously overlooked. BRCA2 mutations in male breast cancer are not necessarily
associated with a positive family history of breast cancer, although halfof our series
did have affected relatives. In four additional cases, a positive family history was
found despite absence of a demonstrable BRCA2 mutation, implying either that
some BRCA2 mutations have been missed or that some cases may be attributable to
mutations in other genes (such as BRCA1) not examined comprehensively in this
study.
We have also shown that a significantly higher proportion of the male breast cancer
cases in our study carry the 203 G->A BRCA2 exon 2 polymorphism compared to a
control population. The effects of this polymorphism, particularly upon gene
expression, require further evaluation.
Carriage of a germline BRCA2 mutation in a male who has developed breast cancer
appears to have no significant effect on age at diagnosis, histological classification of
the tumour, disease stage at presentation, risk of loco-regional relapse within 5 years,
or survival.
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The risk of developing breast cancer among female first-degree relatives ofmale
breast cancer probands is significantly increased, only if the male is a carrier of a
BRCA2 mutation.
Breast cancer penetrance to age 73, of germline BRCA2 mutations in females within
our population is calculated as around 62%.
The findings presented in this study also indicate that the CAG repeat sequence
within the androgen receptor gene may, in some cases, be one useful molecular
marker to identify males at increased risk of developing breast cancer. Larger studies
are required to further define the importance of this CAG repeat in male breast
cancer.
We have found that polymorphisms in the CYP17 and estrogen receptor genes occur
significantly more frequently in male breast cancer patients than in male controls.
We have not found any association between a polymorphic tetranucleotide repeat
sequence in the CYP19 gene and male breast cancer. It is possible that the (TTTA)7
allele of CYP19 has a modifying effect upon the penetrance of some of the BRCA2
mutations found in this study.
Subsequent to our study, an association between a variant in the CHEK2 gene and
male breast cancer has been published. This is another interesting area that requires
further evaluation.
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7.4 Table Of Results For Male Breast Cancer Cases
Case Age Fem
Rels
BRCA2 Cypi7 ARG CYP19 ESR1
Ex2 Mut Intronl | Exon2
MBC1 66 0 G:G T:C 20 7 (-3) 8 T:C G:C
MBC2 69 0 G:A T:C 22 7 (-3) 12 T:C G:G
MBC3 40 0 G:A M T:C 21 7 11 T:C G:G
MBC4 51 0 G:G T:C 25 7 (-3) 11 T:T G:G
MBC6 68 0 G:A C:C 15 7 (-3) 7 T:T G:G
MBC7 64 0 G:G C:C 22 7 (-3) 7 (-3) C:C G:C
MBC8 27 0 G:G T:T 24 7 (-3) 13 T:C G:C
MBC9 75 0 G:A T:C 22 7 (-3) 11 T:C G:G
MBC10 58 0 G:A C:C 19 7 (-3) 11 T:C G:G
MBC11 65 0 G:G T:T 21 11 11 T:C G:C
MBC12 86 0 G:A T:C 20 7 8 T:C G:C
MBC13 71 0 G:G T:T 23 7 11 T:C G:G
MBC14 55 0 G:A T:C 25 7 11 T:T G:G
MBC15 40 0 G:A T:T 23 7 (-3) 12 T:C G:G
MBC16 75 0 G:A T:C 29 7 (-3) 11 T:T G:C
MBC17 67 0 G:G M T:C 23 25 8 11 T:C G:G
MBC18 55 1 G:A M T:C 24 7 (-3) 11 T:C G:G
MBC19 74 0 G:A T:C 24 7 (-3) 8 T:T G:G
MBC20 49 0 G:G T:T 20 8 11 T:T G:C
MBC22 59 0 G:G T:C 25 11 11 T:C G:G
MBC23 73 0 G:A T:C T:C G:C
MBC24 64 0 G:A T:C 25 7 (-3) 7 (-3) T:T G:G
MBC25 82 0 G:G T:C 22 8 12 T:C G:G
MBC26 79 0 G:A M T:T 22 7 (-3) 11 T:C G:G
MBC28 56 1 G:G M C:C 23 7 (-3) 8 T:T G:G
MBC29 72 0 G:G M T:C 7 (-3) 7 T:C C:C
MBC30 30 1 G:G T:T 22 7 (-3) 7 (-3) T:C G:C
MBC31 75 2 G:A M T:C 27 7 11 C:C G:G
MBC32 72 0 G:A T:C 23 7 (-3) 8 C:C G:G
MBC33 76 0 G:A T:C 24 7 11 C:C G:G
MBC34 75 0 G:G T:C 22 11 11 T:C G:G




BRCA2 Cyp17 ARG CYP19 ESR1
Ex2 Mut Intronl Exon2
MBC36 48 0 T:C 24 7 11 T:C G:G
MBC38 48 0 G:G T:C 24 7 8 T:C G:G
MBC40 81 0 G:A T:C 26 7 (-3) 8 C:C G:G
MBC42 70 0 G:A T:C 19 25 T:C G:G
MBC44 70 0 A:A T:C T:C G:G
MBC46 68 1 G:G T:C 25 T:C G:C
MBC49 76 0 G:A T:C 27 7 7 T:T G:G
MBC50 54 0 G:A T:T 22 7 11 T:C G:C
MBC51 64 0 G:A T:C T:C G:G
MBC53 67 0 G:A T:C 20 T:C G:C
MBC54 49 1 G:A T:C 24 27 7 (-3) 11 T:C G:G
MBC55 73 1 G:A M T:C 7 (-3) 12 T:C G:G
MBC56 32 0 G:A M T:T 22 7 11 T:C G:G
MBC57 71 0 A:A T:C 24
MBC58 73 0 A:A T:C 21 8 11 C:C G:G
MBC59 73 0 A:A T:T 22 7 11 T:C G:C
MBC60 85 0 G:A T:C 21 7 (-3) 11 C:C G:G
MBC61 81 0 G:G M T:C C:C G:G
MBC62 51 0 G:A T:C T:C G:C
MBC63 66 3 G:G M T:C 22 7 11 T:T G:G
MBC64 66 0 T:T 21 7 (-3) 11 T:T G:G
MBC65 76 0 G:G T:T 26 7 C:C G:G
MBC66 82 1 T:T 21 11 11 T:C G:G
MBC67 82 0 G:G T:C 20 11 11 T:C G:G
MBC68 85 0 G:A T:T 25 7 (-3) 11 C:C G:G
MBC72 54 0 G:A T:C 24 7 (-3) T:C G:C
MBC73 62 1 G:A M T:T 24 7 (-3) 11 T:T G:G
MBC74 61 0 G:A C:C 22 10 11 C:C G:C
MBC75 83 0 G:G T:C 23 7 (-3) 11 T:C G:G
MBC76 55 0 G:G T:T 24 7 (-3) 7 (-3) T:T G:G
MBC77 50 1 G:G T:C 23 7 (-3) 7 (-3) T:C G:G
MBC78 76 0 G:A T:C T:C G:G
Fem Rels = Number of first-degree female relatives affected with breast cancer
BRCA2 Ex2 = BRCA2 exon 2 allele (G=wild-type, A=polymorphic)
BRCA2 Mut = Those found to carry BRCA2 mutation indicated by 'M'
ARG = Androgen Receptor Gene - Number ofCAG repeats in Exon 1
ESR1 = Oestrogen Receptor Gene
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Short Communication
A polymorphism in the CYP17 gene is associated with
male breast cancer
IE Young', KM Kurian', C Annink'4, IH Kunkler2, VA Anderson3, BB Cohen3, ML Hooper', AH Wyllie'-5 and CM Steel3
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Summary The CYP17 gene codes for the cytochrome P450c17a enzyme that is involved in the synthesis of oestrogens. This case-control
study from the South East of Scotland shows that a polymorphism of the CYP17 gene is associated with an increased risk of male breast
cancer.
Keywords; CYP17 polymorphism; male breast cancer
Mutations of two tumour suppressor genes, BRCA1 and BRCA2,
have been identified in some cases of familial and early onset
breast cancer (Miki et al, 1994; Wooster et al, 1995). These muta¬
tions, however, account for no more than about 5% of total cases
of female breast cancer. Male breast cancer is rare (approximately
1 % of all cases of breast cancer) and therefore less is known about
the genetic influences in its development. Male breast cancer has
been linked to mutations of the BRCA2 gene in some cases. The
frequency of mutations in the series studied varies widely, from
4% to 40% (Thorlacius et al, 1996; Friedman et al, 1997).
It has been suggested there may be other genetic factors that
confer a relatively low absolute risk to the individual, but
potentially could result in a substantial number of cases in the
whole population (Feigelson et al, 1996). The CYP17 gene on
chromosome 10 codes for the cytochrome P450cl7a enzyme
that catalyses steroid 17a-hydroxylase and 17,20-lyase activities
(Picado-Leonard, 1987). It is therefore a key regulator in the
synthesis of androgens and oestrogens from their steroid precur¬
sors (Brentano et al, 1990). A polymorphic T to C substitution has
been described that creates an additional CCACC type promoter
site 34 bp upstream from the site of initiation of translation (Carey
et al, 1994). It is thought that the additional promoter site may
increase the rate of transcription of the gene and thereby increase
enzyme activity. Serum oestradiol levels are higher in women
hetero- and homozygous for the C allele of the CYP17 gene
(Feigelson et al, 1998). One study found that the C allele was
associated with an increased risk of advanced breast cancer
(Feigelson et al, 1997). A larger and more recent study, however,
found no such association (Dunning et al, 1998). Male breast
cancer is known to be associated with conditions, for example
Received 12 January 1999
Revised 10 February 1999
Accepted 12 February 1999
Correspondence to: IE Young
Klinefelter's syndrome, that result in increased levels of serum
oestrogens (Jackson et al, 1965). Mutation of the androgen
receptor gene has also been reported in a few cases of male breast
cancer (Wooster et al, 1992; Lobaccaro et al, 1993). This mutation
results in a change in the androgen-oestrogen balance (low
levels of androgens, increased levels of oestrogens). Given that
the C allele of the CYP17 gene is associated with increased serum
oestradiol levels, then it could also be implicated in the develop¬
ment of male breast cancer. The aim of this study was to test this
hypothesis.
METHODS
Case and control population selection
Male cases were taken from a consecutive series of 76 male breast
cancer patients treated in the South East of Scotland between 1974
and 1998. These patients ranged in age from 26 to 91 years at the
time of diagnosis. Living patients were contacted through their
General Practitioners. Initial contact was by telephone where
possible. Peripheral blood samples (10 ml) were obtained from 24
living male breast cancer patients. Written informed consent was
obtained in all cases. Archival wax-embedded tissue sections were
obtained for 39 deceased patients. DNA previously extracted from
a blood sample and stored was available for one of the deceased
patients. Two patients declined to take part in the study. Archival
specimens were not available in ten cases. Female cases were a
consecutive group of 39 patients with early onset (age < 50 years)
breast cancer referred to the Edinburgh Breast Unit, Western
General Hospital, Edinburgh between 1987 and 1990.
Male and female control DNA samples were extracted from
blood donations to the Edinburgh and South East Scotland Blood
Transfusion service, from placental tissue and blood donations
to the School of Biological and Medical Sciences, University of
St Andrews, and from a small number of tonsillectomy specimens
provided by the Department of ENT Surgery, City Hospital,
Edinburgh. We believe that these samples are representative of
the population within the South East Scotland region.
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Laboratory methods
DNA extraction was from whole blood by standard phenol-
chloroform extraction. DNA extraction from wax-embedded
tissue was from 10-ji.m sections incubated at 55°C with a lysis
buffer and proteinase K.
The following primers were designed for polymerase chain
reaction (PCR): CYP17S-F, 5'-CAAAAGTCAAGGTGAA-
GATCAG-3'; CYP17S-R, 5'-TAGGGTAAGCAGCAAGAGAG-3'.
These generate PCR fragments 150 base pairs in length, including
the polymorphic site. PCR reactions were performed in 50-pl
aliquots, each containing 1 X buffer, 2 mM magnesium chloride,
100 |i,M deoxynucleoside triphosphates, 100 pmol of each primer,
1 unit of Taq polymerase (Life Technologies™) and approximately
100 ng DNA. The amplification was performed using an
OmniGene thermal cycler (Hybaid, UK) under the following
conditions: initial denaturation at 94°C for 3 min; amplification
for 38 cycles, with denaturation at 94°C for 45 s, annealing at
56°C for 45 s and extension at 72°C for 45 s; final extension at
72°C for 10 min. The PCR products were digested with MspAl
(Promega, Madison, WI, USA) for 90 min at 37°C. The products
were separated by electrophoresis on a 4% agarose gel, staining
with ethidium bromide and identified from photographs of the gel
under ultraviolet illumination.
Data analysis
The association between the C allele of the CYP17 gene and breast
cancer in the male and female subjects and controls was analysed
using x2 tests.
RESULTS
The results showing the genotyping of the cases and controls are
shown in Table 1. The results show that a C allele is found signifi¬
cantly more frequently in male breast cancer patients than in male
controls (x2 = 4.308, 1 d.f., P = 0.038). The odds ratio (OR) for the
risk of a male with a C allele developing breast cancer is calculated
as 2.10 (95% confidence interval (CI) 1.04-4.27). There were no
significant differences between female breast cancer patients and
female controls (x2 = 1.895, 1 d.f., P = 0.169; OR = 0.56, 95%
CI 0.25-1.28). The distribution of alleles in both control groups is
in Hardy-Weinberg equilibrium (Table 2).
DISCUSSION
To our knowledge, this is the first study that attempts to evaluate
the possible role of a polymorphism of the CYP17 gene in the
development of male breast cancer. We have found that the poly¬
morphic T to C substitution within the CYP17 gene occurs signifi¬
cantly more frequently in male breast cancer patients than in male
controls. These results are consistent with other reports that there
may be a hormonal contribution to the development of male breast
cancer (Jackson et al, 1965; Lobaccaro et al, 1993; Wooster et al,
1992). We have also studied a small group of female breast cancer
patients from the same geographical region. We found no associa¬
tion between the presence of a C allele of the CYP17 gene and
female breast cancer. The first study that looked at this polymor¬
phism in female breast cancer patients (Feigelson et al, 1997),
found a significant association only after sub-selecting those
patients that presented with advanced disease. The second, and
much larger, study (Dunning et al, 1998) did find a small increase
in the risk of breast cancer associated with the C allele, but this
increase was not statistically significant. It is possible that the T to
C polymorphism in the CYP17 gene is associated with higher
levels of serum oestrogens, but that because the endogenous
oestrogen level is higher in females than in males, further increase
does not have a significant effect. The association between an
increase in the levels of serum oestrogens and the development of
breast cancer may therefore be detectable only in males, or
perhaps as previously suggested (Dunning et al, 1998), among
post-menopausal females.
Further studies of this type are required, specifically to test for
any association between the polymorphism of the CYP17 gene
and levels of serum oestrogens in males.
Table 1 CYP17 genotype frequencies among breast cancer patients and controls
Genotype Cases (n = 64) Controls (n - 81) Cases (n = 39) Controls [n = 58)
TT 17(26.6%) 35(43.2%) 21(53.8%) 23(39.7%)
TC 42(65.6%) 39(48.1%) 13(33.3%) 28(48.3%)
CC 5(7.8%) 7(8.6%) 5(12.8%) 7(12.1%)
TC/CC 47(73.4%) 46(56.8%) 18(46.2%) 35(60.3%)
Table 2 CYP17 genotype frequencies in controls and expected frequencies under Hardy-Weinberg equilibrium
Male controls Female controls
Observed Expected Observed Expected
TT 35 36.7 23 23.6
TC 39 35.7 28 26.8
CC 7 8.67 7 7.60
(X2 = 0.705, 2 d.f., P = 0.703) (X2 = 0.116, 2 d.f., P = 0.943)
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Letters to the Editor
The CAG repeat within the androgen
receptor gene in male breast cancer
patients
Editor—Mutations of the BRCA1 and BRCA2 tumour
suppressor genes have been identified in some cases of
familial and early onset breast cancer.12Mutations of these
genes, however, account for a relatively small proportion of
the total cases of female breast cancer. Male breast cancer
is a very rare disease, accounting for approximately 1% of
all cases of breast cancer. Less is known about the genetic
influences in its development. Male breast cancer has been
linked to mutations of the BRCA2 gene in some cases, with
the frequency ofmutations varying widely (from 4-40%) in
those series studied.5 4
It has been suggested that there may be other genetic
factors that confer a lower absolute risk to the person, but
potentially could result in a substantial number of cases
within a whole population.5 We have already shown that a
polymorphism in the CYP17 gene is associated with an
increased risk ofmale breast cancer.6
A region within exon 1 of the gene coding for the andro¬
gen receptor (located on chromosome Xqll-12) is highly
polymorphic and contains a variable number of CAG
repeats. The variability of the number of these repeats
between different ethnic populations in the USA has been
studied.7 In vitro studies have shown that a relatively short
CAG repeat sequence increases the level of transactivation
of the androgen receptor.8 The androgen receptor itself
binds dihydrotestosterone and therefore is one factor in the
regulation of the growth ofprostate cells. This may account
for the finding that short CAG repeat sequences have been
associated with a higher risk of developing prostate
cancer."10 Abnormally long sequences of 40 repeats or
more are found in patients with X linked spinal and bulbar
muscular atrophy (Kennedy's disease).11 This disease is
associated with gynaecomastia and reduced fertility,
suggestive of androgen insensitivity. Mutations of the
androgen receptor gene may also result in reduced andro¬
gen receptor function and have been found in a few cases
ofmale breast cancer.1213
The aim of this study was to investigate whether
increased length of the CAG repeat sequence in the andro¬
gen receptor gene is associated with the development of
male breast cancer.
The selection of male breast cancer cases and controls
has previously been described.6 Ethical approval for the
study was obtained through the Lothian Regional Ethics
Committee.
DNA extraction was from whole blood by standard
phenol/chloroform extraction. DNA extraction from wax
embedded tissue was from 10 pm sections incubated at
55°C with a lysis buffer and proteinase K.
Using the published sequence,14 the following primers
were designed (Primer Designer vl.l ©1990 Educational
Software): ARG-F 5'-TGCGCGAAGTGATCCAGA
ACC-3', ARG-R 5-CTCATCCAGGACCAGGTAGCC-
3'. These generate PCR fragments containing the CAG
repeat sequence.
PCR reactions were performed in 50 pi aliquots, each
containing 1 x PCR reaction buffer, 2 mmol/1 MgCl,, 5 pi
JMed Genet 2000;37:139-140
dimethyl sulphoxide, 200 pmol/1 deoxynucleoside triphos¬
phates, 20 pmol of each primer, 1 unit of Taq polymerase
(Life Technologies™), and approximately 100 ng DNA.
The amplification was performed using an OmniGene
thermal cycler (Hybaid, UK) under the following condi¬
tions: initial denaturation at 94°C for three minutes;
amplification for 38 cycles, with denaturation at 94°C for
45 seconds, annealing at 56°C for 45 seconds, and exten¬
sion at 72°C for 45 seconds; final extension at 72°C for 10
minutes.
The products were denatured and then run on 6% poly-
acrylamide gels with a 10 bp DNA ladder. The products
were then ranked in order of length. Three representative
products were sent for automated sequencing
(DNASHEF, Department of Haematology, Royal Infir¬
mary of Edinburgh) to confirm the number of CAG
repeats, and these were used as size standards. The
products were then run again, with those thought to be of
equal length adjacent to each other in order to check the
accuracy of the original estimation of length. A second
re-run was then performed to confirm the accuracy of
the results.
The lengths of the PCR products obtained varied
between 224 bp and 272 bp (corresponding to 14 CAG
repeats and 30 CAG repeats, respectively). PCR was
unsuccessful with DNA extracted from eight of the archi¬
val wax embedded tissue sections.
The distribution of alleles among male breast cancer
patients and controls is shown in fig 1. The median number
of CAG repeats in both groups was 23. There were no sta¬
tistically significant differences between the two groups
(Mann-Whitney test, p=0.916).
Three patients showed evidence of two different alleles
indicating the presence of two X chromosomes (fig 2).
One of these (MBC8) was recorded on the Edinburgh
Cytogenetics Register with a diagnosis of Klinefelter's
syndrome. The other two patients (MBC42 and MBC 62)
had died, but there was no record of clinical suspicion of
Klinefelter's syndrome in their hospital case notes.
Neither fathered any children. The data were reanalysed
following exclusion of these three cases. The median
number of CAG repeats for the remaining 53 male breast
ED Controls (n = 79)
■ Cases (n = 59)
No of CAG repeats
Figure 1 Distribution ofCAG repeats in the androgen receptorgene
among male breast cancerpatients and controls.
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MBC62 MBC 8 MBC42
No of CAG repeats 19:25 23:25 24:27
Figure 2 Genotyping of the three male breast cancer patients carrying
two different alleles of the androgen receptor gene.
cancer patients was also 23. There was still no statistically
significant difference between cases and controls
(p=0.765).
We have not observed any overall difference between the
median CAG repeat length of male breast cancer patients
and controls. However, no males in the control group had
alleles containing more than 28 CAG repeats, whereas two
of the male breast cancer patients had alleles with 29 and
30 repeats respectively. Only one of the male breast cancer
patients had an allele containing 18 repeats or less,
compared to six of the controls. To our knowledge, the
length of this CAG repeat has only been studied in one
group of male breast cancer patients previously.15 There
was found to be no significant difference between male
breast cancer cases and controls. However, sequences of
30 repeats or more were found only among cases. Our
results are consistent with these findings. In addition, it
has been recently observed that women who are carriers of
BRCA1 mutations are at a significantly increased risk of
breast cancer if they carry at least one androgen receptor
gene allele with 28 or more CAG repeats.16 We believe that
a relatively long CAG repeat sequence within the
androgen receptor gene may be implicated in a few cases
of male breast cancer. Conversely, a short CAG repeat
sequence might offer a degree of protection against male
breast cancer.
It is well recognised that Klinefelter's syndrome is asso¬
ciated with an increased risk of male breast cancer.17 One of
the male breast cancer patients in our study was known to
have had Klinefelter's syndrome. Our study of the
androgen receptor gene has enabled us to identify a further
two patients whom we suspect to have had Klinefelter's
syndrome.
The findings presented in this study indicate that the
CAG repeat sequence within the androgen receptor gene
may, in some cases, be one useful molecular marker to
identify males at increased risk ofdeveloping breast cancer.
Larger studies are required to define the importance of this
CAG repeat in male breast cancer further. An international
consortium has recently been set up and we have agreed to
contribute our data to this.
There is also a GGC repeat sequence within exon 1 of
the androgen receptor gene. This might be an interesting
area for further study.
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Summary The CYP19 gene codes for the aromatase enzyme that is involved in the synthesis of oestrogens. This case-control study
examines the relationship between a tetranucleotide repeat sequence in the CYP19 gene and the development of male breast cancer. No
significant differences were found between male breast cancer cases and controls. © 2000 Cancer Research Campaign
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The CYP19 gene (located on chromosome 15q21.1) codes for the
aromatase enzyme that controls the rate-limiting step in the
pathway of oestrogen synthesis from steroid precursors. It is
known that an increased risk of breast cancer in males is associated
with elevated serum oestrogen levels, for example in Klinefelter's
syndrome (Jackson et al, 1965). The aromatase enzyme has been
observed within the stromal cells in a greater proportion of male
breast carcinomas than gynaecomastia cases, suggesting that
locally produced oestrogens may also have a significant role in the
development ofmale breast cancer (Sasano et al, 1996). It is there¬
fore possible that variation in expression of the CYP19 gene could
affect the risk of developing male breast cancer.
A polymorphic tetranucleotide (TTTA) repeat sequence is
found in intron 5 of the CYP19 gene, 79 nucleotides downstream
from exon 4 (Means et al, 1989). This repeat sequence is relatively
close to the exon-intron border and may therefore be involved in
the determination of splicing sites (Kristensen et al, 1998). The
aim of this study was to determine whether the development of
male breast cancer is influenced by the length of this tetra¬
nucleotide repeat sequence in the CYP19 gene.
METHODS
Case and control population selection
Male cases were taken from a consecutive series of 76 male breast
cancer patients treated in the South East of Scotland between 1974
and 1998. Samples were available for DNA extraction in 64 of
these cases. Control DNA samples were obtained from 79 healthy
males representative of the South East Scotland population.
Further details of male breast cancer cases and controls have
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previously been described (Young et al, 1999). Ethical approval
for the study was obtained through the Lothian Regional Ethics
Committee.
Laboratory methods
DNA extraction was carried out from whole blood by standard
phenol-chloroform extraction. DNA extraction from wax-
embedded tissue was from 10-pm sections incubated at 55°C with
a lysis buffer and proteinase K.
Primers as previously described (Polymeropoulos et al, 1991)
were used for polymerase chain reaction (PCR): CYP19-F:
5'-GCAGGTACTTAGTTAGCTAC-3'; CYP19-R: 5'-TTACAGT-
GAGCCAAGGTCGT-3'. These generate PCR fragments that
include the polymorphic site. PCR reactions were performed in
50-|il aliquots, each containing 1 x buffer, 2 mM magnesium chlo¬
ride (MgCl,), 200 jim deoxynucleoside triphosphates, 40 pmol of
each primer, 1 unit of Taq polymerase (Life Technologies™) and
approximately 100 ng DNA. The amplification was performed
using an OmniGene thermal cycler (Hybaid, UK) under the
following conditions: initial denaturation at 94°C for 3 min;
amplification for 38 cycles, with denaturation at 94°C for 45 s,
annealing at 53°C for 45 s and extension at 72°C for 45 s; final
extension at 72°C for 10 min.
The products were denatured and then run on 6% polyacryl-
amide gels with a 10 bp DNA ladder. The number ofTTTA repeats
in homozygous products were measured by cycle sequencing and
these were used as size standards.
Data analysis
The distribution of alleles of the CYP19 gene, comparing male
breast cancer patients with controls, was analysed using the
Mann-Whitney test. Odds ratios with 95% confidence intervals
were calculated to show the risk of developing male breast cancer
associated with each allele.
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10 bp DNA MBC20F MBC20
No. TTTA Repeats 7(_3) 8 10 11 12 13 13
7(-3) 7 7 11 7 7(—3) 11
Figure 1 Examples of the seven different alleles of the CYP19 gene found
in male breast cancer patients and controls
Table 1 Distribution of alleles of the CYP19 gene in male breast cancer
patients and controls
Allele PCR product Cases Controls Odds ratio & 95%
length (bp) (n = 108) (n = 158) confidence interval
(TTTA),,, 168 35 (32.4%) 48 (30.4%) 1.10(0.649-1.86)
(TTTA), 171 20(18.5%) 30(19.0%) 0.970 (0.518-1.82)
(TTTA), 175 11 (10.2%) 16(10.1%) 1.01 (0.448-2.26)
(TTTA),, 183 1 (0.93%) 2(1.3%) 0.729 (0.0653-8.14)
(TTTA),, 187 36 (33.3%) 57 (36.1%) 0.886 (0.529-1.48)
(TTTA),, 191 4 (3.7%) 5 (3.2%) 1.18 (0.309-4.49)
(TTTA),, 195 1 (0.93%) 0 -
Heterozygosity 79.6% 79.7%
RESULTS
PCR was unsuccessful with ten of the DNA samples derived from
archival wax-embedded tissue sections, giving a total of 54 case
samples (108 alleles) analysed.
Seven different alleles of the CYP19 gene were detected
(Figure 1). The allele distribution of the CYP19 gene in male
breast cancer patients and controls is shown in Table 1. There were
no significant differences in the distribution of alleles between
cases and controls (P = 0.838). We have found two different alleles
containing seven TTTA repeats (corresponding to PCR products
of 168 bp and 171 bp in length). Cycle sequencing of these alleles
revealed that the shorter allele, designated (TTTA), 3, had a 3-bp
(TTC) deletion 50 bp upstream from the 5' end of the TTTA repeat
sequence. One of the male breast cancer patients (MBC20) had an
allele containing 13 repeats. A blood sample was obtained from
his father (MBC20F), who had not had breast cancer. Analysis of
DNA extracted from this showed the same (TTTA)13 allele.
DISCUSSION
This is the first study that attempts to determine whether the devel¬
opment of male breast cancer is influenced by the length of the
tetranucleotide repeat sequence within intron 5 of the CYPI9 gene.
Two recent studies have determined the distribution of alleles
among female breast cancer patients and controls. The first of
these studies (Kristensen et al, 1998) found five different alleles
British Journal of Cancer (2000) 82(7), 1247-1248
containing 7, 8, 9, ll and 12 repeats. The allele containing 12
repeats was found significantly more frequently in female breast
cancer patients than in controls. The second of the studies
(Siegelmann-Danieli and Buetow, 1999) described eight different
alleles by PCR product length. Details of TTTA repeat number
were not given. Alleles of 168 bp and 171 bp in length were found,
presumably corresponding to the two different alleles containing
seven repeats found in our study, although the 3-bp deletion was
not characterized. This deletion has, however, been described
previously in a Japanese study (Kurosaki et al, 1997). From their
study, Siegelmann-Danieli and Buetow (1999) conclude that the
171 bp allele represents a high-risk allele, whereas the 187 bp and
191 bp alleles (corresponding to 11 and 12 repeats respectively,
from our data) are considered to confer low risk. These conclu¬
sions are contradictory to those drawn by Kristensen et al (1998).
Contrary to published (and mutually incompatible) findings in
female breast cancer, our study found no significant differences in
distribution of alleles between male breast cancer cases and
controls. Patient MBC20, who has an allele with 13 repeats, was
diagnosed with breast cancer at a very young age (26 years), but
has no family history of cancer. This certainly represents a rare
variant within the South East Scotland population, but is most
likely to be an incidental finding.
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BRCAI and BRCA2 mutations in Scotland and Northern Ireland
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BRCAI and BRCA2 mutations have been identified in 107 families in Scotland and Northern Ireland. Ninety-seven of these families
had been referred to regional cancer genetics centres and a further 10 were identified from a sequential series of male breast cancers
treated in Edinburgh. Fifty-nine of the families had a mutation in BRCAI and 46 in BRCA2. Two families had both. Family trees were
extended and cancer diagnoses verified by means of the unusually complete and accessible Scottish and Northern Irish records. Ten
specific recurring mutations (five in each gene) accounted for almost half of the total detected, and almost one-quarter were
accounted for by just two (BRCAI 2800 delAA and BRCA2 6503 deITT). The prevalence of breast cancer is similar for BRCAI and
BRCA2 mutation families (average 3.7 and 3.6 per family), but the former have a much greater risk of ovarian cancer (average 1.5 and
0.6 per family, respectively). For breast cancer, age of onset tended to be younger in BRCAI mutation carriers but, for ovarian cancer,
there was no difference between BRCAI and BRCA2 families in mean age at diagnosis. Mutations within the 5' two-thirds of BRCAI
carry a significantly higher relative risk of ovarian cancer and the same is true for mutations within the central portion of BRCA2 (the
'OCCR'). In the former case, this appears to be because of differences in absolute risk for both ovarian and breast cancer, while, in the
latter, only ovarian cancer risk varies significantly. The findings confirm that founder mutations are present within the Scottish/
Northern Irish population and have implications for the organisation of molecular screening services.
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Worldwide variation in the distribution of BRCAI and BRCA2
mutations is well recognised (Szabo and King, 1997). In several
populations or ethnic groups, distinctive founder mutations form a
sufficient proportion of the total to justify the adoption of specific
molecular screening strategies (Levy-Lahad et al, 1997; Peelen et al,
1997; Thorlacius et al, 1997; Moller et al, 2001). In the UK, there
has been only limited evidence to date of founder mutations
(Gayther et al, 1995, 1997; Eccles et al, 1998; Lancaster et al, 1998;
Peto et al, 1999), the most clear-cut example being BRCAI 2800
delAA, probably originating from the West of Scotland or Ireland
(Liede et al, 2000). Since the present day populations of Scotland
and Northern Ireland remain relatively homogeneous, and distinct
from those of other parts of the UK (Bodmer et al, 1987; Liede et al,
2000), we have collated information on all BRCAI and BRCA2
mutations recorded among families attending breast cancer
genetics clinics in Aberdeen, Belfast, Dundee, Edinburgh or
Glasgow. Additional data are included from a sequential series of
male breast cancers presenting in South-East Scotland (Young et al,
2000). Findings are compared with those reported from England,
Wales and elsewhere.
In both Scotland and Northern Ireland, families have tended to
be large, at least until the current generation. They are also,
typically, close-knit, maintaining contact even with members who
have emigrated to distant parts of the world. Records of births,
marriages and deaths are unusually complete and accessible
*Correspondence: Professor CM Steel; E-mail: cms4@st-and.ac.uk
+ For list of members, see Appendix I
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(Collyer and DeMey, 1987) and the Scottish Cancer Registry, in
particular, is recognised as among the best in the world (Kemp
et al, 1985). For all these reasons, data on Scottish and Northern
Irish families with genetic disorders can be extensive and accurate.
The present data set, based on over 100 mutation-bearing families,
is therefore of value for addressing questions about the clinical
implications of BRCAI and BRCA2 mutations.
PATIENTS, FAMILIES AND METHODS
The study was approved by the Medical Research Ethics
Committee for each of the regions in which clinical genetics
services are based. The five centres mentioned above provide
comprehensive National Health Service (NHS) clinical services for
familial cancers, covering the entire population. They have
collaborated closely in the design and development of these
services for some 10 years and follow common policies on
eligibility for regular surveillance by clinical/mammographic and
ovarian screening (Haites et al, 2000). Molecular testing for BRCAI
or BRCA2 mutations was available only on a research basis from
1994 until 2001, when NHS funding was provided to establish a
laboratory service accessible to all high-risk families. The majority
of mutations included in this report were identified in one of the
Scottish or Northern Irish research centres but some were found in
family members tested at the Institute ofCancer Research, London
(Dr Simon Gayther, Prof Michael Stratton), the University of Lund
(Dr Ake Borg) or in centres in the USA, Australia, Iceland and the
Netherlands. Mutation-detection methods therefore varied but, in
general, they have been based on PCR amplification of gene
fragments, covering most of the coding regions and splice sites,
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followed by SSCP or heteroduplex analysis on gels (Gayther et al,
1995, 1996) or, more recently, by DHPLC (Wagner et al, 1999).
Protein truncation assay (Hogervorst et al, 1995) has been applied
on a limited scale and 150 samples from 'high-risk' families were
screened specifically for the 6kb duplication in BRCA1 exon 13,
with one positive result (Mazoyer et al, 2000). Only some 20 'high-
risk' Scottish families have been included in a preliminary screen
for large deletions in BRCA1. None has yet been found. Some
centres have concentrated on screening those regions of both
genes where mutations have already been identified in our
population. This is likely to increase the apparent frequency of
recurrent mutations but it is difficult to quantify the effect. The
bulk of the screening was undertaken without this bias and, where
priority was given to examination of particular PCR fragments,
these, in total, represent a significant proportion of the entire
coding regions of BRCA1 and BRCA2, so that nonrecurring
mutations could be (indeed were) detected in the process. All
mutations have been confirmed by direct sequencing and
reconfirmed on a second blood sample from the index case before
offering counselling and access to genetic testing for at-risk adult
members of the family.
Family trees have been constructed, initially from information
provided by families themselves. In most instances, they have filled
out detailed family history forms, issued on referral to a genetics
clinic. This normally entails a collaborative effort on the part of
several family members, across the generations. Verification and
extension of pedigrees can be undertaken by consulting public
registration records (Collyer and DeMey, 1987) which, in
comprehensive form, date from 1855. This facility, supported by
a professional medical genealogist, is used selectively but when a
germline mutation is detected, record tracing becomes a priority,
since the process can establish links between two or more families
already known to the clinics.
All practicable efforts are made to verify reported cancer
diagnoses in the family, particularly if it seems probable that the
pattern of disease is attributable to a high penetrance mutation.
Confirmation can be obtained, in the case of deceased subjects, by
consulting the Scottish or Northern Irish cancer registries (good
data are available from mid-1960s onwards). For living patients,
permission is sought to check relevant details from hospital
records. In some instances, particularly for cancers that occurred
over 40 years ago, supporting evidence can be obtained only from
death certificates and, on occasions, there is no means of
verification. A judgement then has to be made, on the basis of
the family's own knowledge, whether or not to record a given
relative as being affected by breast, ovarian or other cancers. When
a mutation has been identified in one member of a given family,
blood samples or tissue blocks are sought from affected relatives,
to establish their mutation status. The process of tracing the
distribution of the mutant allele within each family is still ongoing.
In a number of cases, affected relatives have been shown not to
carry the 'family mutation'. These individuals are usually then
reclassified as having sporadic cancer (with correspondingly
reduced risk estimates for their descendants) but in two families
a second mutation has been found and, in a few more, the pattern
of cancers on both sides of the pedigree would be consistent with
the presence of a second, still unidentified, mutation.
In the main, families selected for molecular testing met the
published criteria (Haites et al, 2000) for, at least, 'moderate risk'
(i.e. two close relatives with early onset breast or ovarian cancer)
and most met the more stringent criteria defining 'high risk'. Two
exceptions were a single positive result from a consecutive series of
women diagnosed with breast cancer under age 50 and one patient
who had only a single relative with breast cancer, but an unusual
familial cluster of early onset prostate, stomach and laryngeal
cancers. She herselfmight have been discharged but was found to
have breast cancer on her first clinic visit and a BRCA2 mutation
was subsequently demonstrated. Twelve BRCA2 mutations have
been identified among DNA samples from a consecutive series of
64 male breast cancers treated in Edinburgh since 1975. These
samples were analysed, in the first instance, without reference to
family history (Young et al, 2000). Most of the patients are
deceased and construction of complete family trees is still
proceeding, with the cooperation of their living relatives. However,
two of them belong to families already registered with the regional
cancer genetics clinic (because a cluster of cases among relatives
had been recognised). In addition to the 12 from the consecutive
series, a further 10 instances of male breast cancer have been
recorded among the BRCA2 mutation-positive families in the
present report. Two of these families included more than one
affected male (three and two cases each).
RESULTS
One hundred and nine mutations (61 in BRCA1, 48 in BRCA2)
have been identified in 107 families. The vast majority cause
truncation of the protein product (89 frame-shifts, six nonsense
substitutions, eight splice site disruptions). One is a 6kb
duplication of BRCA1 exon 13 and there are two instances of an
intronic deletion believed to affect splicing (BRCA2 9877-67 del4).
Only three missense substitutions are included. Two of these are
recognised as pathogenic by the Breast Cancer Information Core
(BIC) database and the third, BRCA1 5242C>A, although still
listed as an unclassified variant, has been recorded 13 times in
multicase breast cancer families.
Several mutations have been identified in more than one family
each. Two are particularly frequent, BRCA1 2800 delAA and
BRCA2 6503 delTT. The former has already been identified as a
Scottish/Irish founder mutation (Liede et al, 2000), while the latter
is also a recognised founder mutation, distributed throughout
Europe and the USA (Mazoyer et al, 1996; Szabo and King, 1997;
BIC database). In contrast to BRCA1 2800 delAA, the BRCA2 6503
delTT mutation is relatively frequent among families attending the
Aberdeen and Dundee clinics (representing the North and East of
Scotland), which may be in keeping with Scandinavian origin
(Table 1).
Eight further mutations, each detected at least three times,
account for 27 families. Two of the three recognised Ashkenazi
Jewish mutations (Levy-Lahad et al, 1997) -BRCA1 185 delAG and
BRCA1 5382 insC - are among these eight; the third, BRCA2 6174
delT, was found on two occasions. The overall distribution of
mutations is set out in Figure 1.
In assessing the numbers of breast and ovarian cancers recorded
in mutation-positive families, two families have been excluded
(both with BRCA2 mutations). One was identified through the
consecutive series of male breast cancers and no information has
yet been obtained about relatives. The other has been counted as a
BRCA1 mutation family, although a single BRCA2 mutation-
Table I Geographical distribution of BRCAI and BRCA2 founder
mutations






Numbers of families with founder mutations BRCAI 2800 delAA or BRCA2 6503
delTT attending each of the five clinics in Scotland/Northern Ireland. Some families,
with branches in different parts of the country, are recorded as attending more than
one clinic. Clinics are listed in geographical sequence from North-East (Aberdeen) to
South-West (Belfast).
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Figure I Diagrammatic representation of BRCA I exons (plus intronic regions with pathogenic mutations, shown shaded). Vertical lines above the
diagram represent all mutations detected, with heights proportional to numbers of cases. Actual numbers are given for most frequent mutations. Circles
below the diagram represent families with at least three breast or ovarian cancers attributed to each mutation. The darker segment of each circle represents
the proportion of breast cancers and the paler segment the proportion of ovarian cancers.
carrier has been identified in one branch of the pedigree. That
branch has not yet been investigated in detail. For the other family
with two mutations (BRCA1 and BRCA2), it has been possible to
identify the separate routes of inheritance and hence to calculate
the numbers of breast and ovarian cancers attributable to each
mutation. For all families, where an affected individual has been
found not to carry the BRCA1 or BRCA2 mutation, that tumour
has not been included in the calculations and, of course, only
tumours occurring in blood relatives of mutation-positive family
members are counted. Overall, comparable effort has been
expended on gathering and verification of data on BRCA1 and
BRCA2 mutation families. As shown in Table 2, the average
number of breast cancers recorded per family is virtually the same
for both mutations, but there are two and a half times as many
ovarian cancers in BRCA1 families. The ratio of breast to ovarian
cancers is 2.39:1 for BRCA1 families and 6.18:1 for BRCA2
families, a difference which is significant at the 0.01% level by y2
analysis. This is consistent with data from the Breast Cancer
Linkage Consortium (Ford et al, 1998) and other sources (Risch
et al, 2001; Welcsh and King, 2001).
The mean age at diagnosis of breast cancer in BRCA1 mutation
carriers was 42.6 years (95% CI 40.5-44.8). For BRCA2 mutation
carriers (females only), it was 46.5 years (95% CI 43.6-49.4). Half
of those with BRCA1 mutations were diagnosed at or below age 40,
compared with just over one-quarter of those with BRCA2
mutations. For affected males (all with BRCA2 mutations), mean
age at diagnosis of breast cancer was 59.4 years (95% CI 51.9—
67.0). In keeping with the younger age at onset, 56% of BRCA1
families included at least one instance of bilateral disease,
compared to 28% of BRCA2 families. (In the latter set, there was
one male with bilateral breast cancers, onsets separated by 22
years.) Furthermore, in 36% of BRCA1 families, but fewer than
10% of BRCA2 families, there were two or more examples of
bilaterality. Individual women with both breast and ovarian cancer
were recorded in 36% of BRCA1 families, with up to three
instances per family, whereas they occurred in only 10% of BRCA2
families and no family included more than one case. Ages of onset
for ovarian cancer did not differ between families with BRCA1 or
BRCA2 mutations (49.7 years, 95% CI 46.9-52.4 and 49.8 years,
95% CI 43.0-56.6 years, respectively). Over 90% of ovarian
cancers, in both sets of families, were diagnosed at age 40 or older
and half of the remainder were diagnosed at age 39.
A rather more contentious issue is the effect of mutation
position, within either gene, on the relative risk of breast or
ovarian cancer (Gayther et al, 1995; Iau et al, 2001; Thompson et al,
2001). For BRCA1, there is evidence that mutations towards the 3'
end are less likely to be associated with ovarian cancer (Gayther
et al, 1995). We have subdivided our BRCA1 families as shown in
Tables 3A, B, and confirm that the ratio of breast to ovarian
cancers is strongly influenced by mutation site. Interestingly, our
data suggest that this may result from both an increase in breast
Table 2 Breast and ovarian cancers recorded in BRCA I and BRCA2
mutation-bearing families
BRCAI mutation +ve BRCA2 mutation +ve
No. of families 61 46
No. of breast cancers 225 167
No. of ovarian cancers 94a 27b
Av. breast cancers/family 3.7 3.6
Av. ovarian cancers/fam 1.5 0.6
Ratio CaBr/CaOv 2.39:1 6.19:1
alndudes one primary peritoneal carcinoma. Includes one primary carcinoma of
fallopian tube.
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Table 3 Distribution of breast and ovarian cancers in families, according
to site of (A) BRCA I and (B) BRCA2 mutation
(A) BRCAI mutations BRCAI mutations
5' of exon 12 exons 12-24
Number of families 49 12
No. of breast cancers 161 64
No. of ovarian cancers 82 12
Average CaBr/family 3.3a 5.3a
Average CaOv/family 1.7 1.0
Ratio CaBr/CaOv 1.96:1b 5.33:1"
(B) BRCA2 mutations BRCA2 mutations
within 'OCCR' outside 'OCCR'
Number of families 25 21
No. of breast cancers 101 66
No. of ovarian cancers 21 6
Average CaBr/family 4.0 3.1
Average CaOv/family 0.84c 0.29c
Ratio CaBr/CaOv 4.8l:ld 1 !:ld
"■Difference in risks of breast cancer P = 0.001 (by y2). bDifference in relative risks of
breast vs ovarian cancer, P = 0.0002 (by y2). difference in risks of ovarian cancer
P<0.02 (by y2). difference in relative risks of breast vs ovarian cancer P< 0.005
(by y2)-
cancer risk and a reduction in ovarian cancer risk when the
mutation occurs 3' of exon 11.
For BRCA2, it has been proposed that mutations within the
central region of the gene, termed the ovarian cancer cluster region
('OCCR')> are particularly associated with ovarian cancers
(Figure 2). Our data show that the ratio of breast to ovarian
cancers is 4.81:1 for mutations within the OCCR and 11.0:1 for
mutations 3' and 5' of that region. When the families identified
only through the male breast cancer study are excluded, the trend
for ovarian cancer remains in the same direction (4.04 breast
cancers and 0.84 ovarian cancer per family within OCCR, 4.33
breast cancers and 0.50 ovarian cancers per family outside it; ratios
4.81:1 and 8.67:1, respectively) but the differences are no longer
statistically significant.
DISCUSSION
The proportion of BRCA2 mutation-bearing families in the present
series (44%) is higher than that has been estimated indirectly from
earlier (mainly much smaller) studies from the UK (Szabo and
King, 1997; Lancaster et al, 1998). However, it is consistent with
the prediction of roughly equal prevalence of BRCA1 and BRCA2
mutations, based on a survey of very early onset breast cancers
(Peto et al, 1999). The authors of that survey noted that several UK
studies have concentrated on multicase families in which ovarian
cancer was prominent, thus overestimating the relative frequency
of BRCA1 mutations. The International Breast Cancer Linkage
Consortium data show that, among families with multiple cases of
breast cancer but no known ovarian cancers, BRCA1 and BRCA2
mutations are almost equally represented (Ford et al, 1998). In the
present series, there was no particular emphasis on ovarian cancer
in selecting families for mutation testing but, of course, the
clustering of ovarian with breast cancer in a family adds
considerably to the prior probability of a mutation being present,
as also does the occurrence of very early onset breast cancer.
Account is taken of both these facts in the Scottish NHS guidelines
I I i_
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Figure 2 Diagram of BRCA2 exons, with the position of the 'OCCR' indicated. Annotation and symbols are as for Figure I.
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for management of familial cancers (Haites et al, 2000), hence
favouring ascertainment of BRCA1 mutation-bearing families. In
most centres, facilities for BRCA1 mutation testing became
available at least a year before those for BRCA2 so that, in
consecutive series, there is some bias in favour of detecting BRCA1
mutations. This applies to the present data set, although the effect
is probably not great and should diminish with time. On the other
hand, our inclusion of 10 BRCA2 mutations detected only through
a survey of male breast cancers obviously introduces a bias in the
opposite direction. Nevertheless, it appears that in Scotland and
Northern Ireland, the relative prevalence of BRCA2 mutations may
be higher than in some other regions of Europe such as Norway
(Moller et al, 2001), Sweden (Hakansson et al, 1997), Belgium
(Claes et al, 1999) or France (Serova-Sinilnikova et al, 1997;
Stoppa-Lyonnet et al, 1997).
Our findings do not permit any calculation of the absolute
prevalence of BRCA1 or BRCA2 mutations in the Scottish and
Northern Irish populations but they add to our knowledge of the
distribution of specific mutations. Allowing for some bias in
ascertainment, as discussed above, almost one-quarter of the
families are accounted for by just two (BRCA1 2800 delAA and
BRCA2 6503 delTT) and almost half by the 10 mutations that were
found in at least three families each. Two of these are the well-
recognised 'Ashkenazi Jewish' BRCA1 mutations (185 delAG and
5382 insC), although at least one of the affected families is unaware
of any Ashkenazi Jewish ancestry. The other recurring mutations
are BRCA1 3477 delGT and 4184 del4, BRCA2 1418 ins4, 5445 del7,
7165 + 2 delT, 7830 dell6. Most of these have been recorded many
times in the BIC database and/or the Human Gene Mutation
Database. Our earlier speculation (Liede et al, 2000) that BRCA1
2800 delAA may have originated in West-Central Scotland or in
Ireland seems to be supported by the finding of three further cases,
one from Glasgow and two from Belfast. BRCA2 6503 delTT has
been found elsewhere in the UK as well as in Dutch, Swedish,
Danish and Belgian families (BIC database). It was the most
frequently recurring BRCA2 mutation (four examples) among 25
recorded by Gayther et al (1997) from 'the United Kingdom and
Eire' but no further breakdown by geographical region was
provided. BRCA1 4184 del4 was identified as a recurring mutation
in that survey and also in separate reports of families from Wales
and the South of England (Lancaster et al, 1998; Eccles et al, 1998).
In the last-mentioned study, BRCA1 3875 was found five times in a
total series of 17 mutations. It is entirely possible that further
examples may be found of founder mutations associated with
specific populations concentrated in particular regions of the UK
but larger studies will be required. Scotland and Northern Ireland
offer special advantages for this kind of analysis because of the
relative population stability, the existence of an NHS-funded
cancer genetics network and the excellence of genealogical and
health-related records.
The proportion of all breast or breast/ovarian cancer families in
our population attributable to recurring BRCA1 or BRCA2
mutations appears to be lower than in some other countries such
as Iceland (Thorlacius et al, 1997), Israel (Levy-Lahad et al, 1997)
or Norway (Moller et al, 2001), comparable to that in the
Netherlands (Peelen et al, 1997; Claes et al, 1999), but much
higher than in others, such as Italy (Szabo and King, 1997;
Cippolini et al, 1999), and sufficient to have practical implications
for the formal organisation of molecular screening. A first-stage
analysis, covering the 10 most common BRCA1 and BRCA2
mutations, using multiplex PCR/DHPLC is rapid and relatively
inexpensive. It can be offered to substantial numbers of families,
then, if a negative result is obtained, more stringent risk criteria
can be applied for complete analysis of the genes. This policy is
already identifying further mutation-positive families (not in¬
cluded in the present report) among those who would not
currently be eligible for full-scale molecular screening in our
diagnostic laboratories (Haites et al, 2000). The occurrence of
identical mutations in many families also provides opportunities
for investigation of genetic and environmental factors that may
modify penetrance or expression of the underlying mutation. This
principle has been applied, for example, to identify an interaction
between BRCA2 mutations and a polymorphism of RAD51 (Levy-
Lahad et al, 2001; Wang et al, 2001). Among the families recorded
here is one with seven cases of ovarian cancer over four
generations, but no breast cancers. No other family with the same
mutation, from the present series or from the BIC database, shows
a comparable distribution of tumours and further research is
warranted to establish whether this is merely a chance finding or a
clue to an additional causal factor.
The influence of mutation site on relative risk of breast or
ovarian cancer has been a controversial issue. For BRCA1, two
studies published in 1995 indicated that the relative risk of ovarian
cancer was substantially higher for mutations occurring in the 5'
two-thirds of the gene (Gayther et al, 1995; Shattuck-Eidens et al,
1995) but this was not confirmed in three other reports (Serova
et al, 1996; Couch et al, 1997; Frank et al, 1998) and is not apparent
in a fourth (Eccles et al, 1998), where the data are presented but
not discussed in detail. Taking the 3' end of exon 11 as the
potential 'change point', we found a highly significant difference in
the relative proportions of breast and ovarian cancers 'upstream'
and 'downstream' of this position. Furthermore, the difference
seems to arise both from an increased risk of breast cancer and a
reduced risk of ovarian cancer for mutations in the 3' third
of the gene, although the difference in numbers of breast cancers
per family does not achieve statistical significance on its own
(P<0.1).
For BRCA2, an 'Ovarian Cancer Cluster Region' in the middle
third of the gene was proposed by Gayther et al (1997). An
international collaborative study (Neuhausen et al, 1998) provided
some supporting evidence which, however, failed to reach
statistical significance. In a more recent analysis of 164 BRCA2
mutation-bearing families (Thompson et al, 2001), 23.8% of
tumours were ovarian (and 76.2% breast) among families with
OCCR mutations: for families with mutations 5' and 3' of the
OCCR, 8.8 and 9.6%, respectively, were ovarian cancers. Our own
findings are similar but, whereas Thompson and colleagues found
that a reduced absolute risk of breast cancer for OCCR mutations
contributes substantially to the effect, in our series, the number of
breast cancers per family is actually higher for OCCR vs non-OCCR
mutations, and the entire increase in relative risk of ovarian cancer
is attributable to a 2.9-fold higher rate of ovarian cancers in the
former group. It will be important to determine which of these
interpretations is correct in order to generate testable biological
hypotheses to explain the findings.
The validity of our analysis depends on completeness of
ascertainment of families and accuracy of breast and ovarian
cancer diagnoses. There are obviously limitations on both counts
but the large average family size, the accessibility of confirmatory
records and the uniformity of our approach to extension and
verification of family data allow some confidence in our data.
Excluding nine families ascertained only through a series of male
breast cancers (one such family was already excluded for lack of
information) greatly reduces the statistical power of our analysis. It
happens that all of these nine families carried mutations outside
the OCCR and that none included any case of ovarian cancer.
However, there is no indication that these are particular
characteristics of BRCA2 mutations associated with male breast
cancer. Six of the families with mutations inside the OCCR
included affected males (two with more than one male case each)
and two of these also included ovarian cancers.
Whether the associations between mutation position and
phenotype are sufficiently strong to influence genetic counselling
and management of affected families remains a moot point.
Individual families, where the distribution of cancers seems to
depart from the general rules, are not rare and, for the present, it
British Journal of Cancer (2003) 88(8). 1256- 1262 ) 2003 Cancer Research UK
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may be wise to take at least as much account of the previous
history of the family in question as of the statistical findings from
large-scale surveys.
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